files.cpicpgx.org1000truedata/2018-12-11T18:04:33.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/database/2020-05-13T20:16:07.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/database/cpic_db_dump-20200507.sql.gz2020-05-13T20:16:12.000Z"821a25e6ff30d8dc84e734a73437d978"652133STANDARDdata/database/cpic_db_dump-20200516.sql.gz2020-05-17T04:47:22.000Z"3f334c7b8002c1cf23f4b8608701ec72"652710STANDARDdata/database/cpic_db_dump-20200527.sql.gz2020-05-27T17:42:36.000Z"04fd0483998576281d9052b3d21e7a52"652008STANDARDdata/database/cpic_db_dump-20200707.sql.gz2020-07-08T03:43:24.000Z"b38116764a7a21a8ec4ef0eee1f31459"742082STANDARDdata/database/cpic_db_dump-v.1.17.1.sql.gz2022-05-05T22:48:51.000Z"c93052efdc2af2322662584a64606f3d"1627532STANDARDdata/database/cpic_db_dump-v.1.17.1_inserts.sql.gz2022-05-05T22:48:52.000Z"ac5aca92a7663a0f668d2f4833b71ddc"1856089STANDARDdata/database/cpic_db_dump-v0.10.sql.gz2020-10-01T03:50:43.000Z"865f406a19af1ff60d02c07f26b9f47b"1055650STANDARDdata/database/cpic_db_dump-v0.11.sql.gz2020-10-29T03:05:41.000Z"e5498898a28c37edeb3fdc19204a5f18"1143624STANDARDdata/database/cpic_db_dump-v0.8.1.sql.gz2020-08-17T02:52:21.000Z"f13e329d59c7c92964f1b42152fb6004"989725STANDARDdata/database/cpic_db_dump-v0.8.sql.gz2020-08-14T21:05:03.000Z"6cb9245e99682896ccb794455881e12f"796772STANDARDdata/database/cpic_db_dump-v0.9.sql.gz2020-09-16T03:10:32.000Z"3e1519e561014eb0ba0f3d88e6a5e595"1002708STANDARDdata/database/cpic_db_dump-v1.0.sql.gz2020-11-04T23:34:09.000Z"1e2b064029e66c3534b8b4388134a425"1268676STANDARDdata/database/cpic_db_dump-v1.1.sql.gz2021-01-08T01:48:10.000Z"262c7bcb8774e47d24cb65f46e11de50"1289502STANDARDdata/database/cpic_db_dump-v1.10.sql.gz2021-10-25T20:18:44.000Z"33e4b7cebaccaaf8417615c465b1a61d"1401988STANDARDdata/database/cpic_db_dump-v1.10_inserts.sql.gz2021-10-25T20:18:45.000Z"61f46550216c906dcc4c9e811b1cb0a5"1607475STANDARDdata/database/cpic_db_dump-v1.11.sql.gz2021-12-07T16:35:45.000Z"24a0e7ebc17c98ded96c5f1a19a515dc"1417131STANDARDdata/database/cpic_db_dump-v1.11_inserts.sql.gz2021-12-07T16:35:46.000Z"c929890c98b0d31fe1acd8c5bb8c41e5"1623837STANDARDdata/database/cpic_db_dump-v1.12.sql.gz2022-01-10T17:01:12.000Z"26706b345eb032e127e5d927166255f5"1426241STANDARDdata/database/cpic_db_dump-v1.12_inserts.sql.gz2022-01-10T17:01:13.000Z"750bd96915ec0ffce743487348c06e6d"1633152STANDARDdata/database/cpic_db_dump-v1.13.sql.gz2022-02-16T23:19:56.000Z"93bb7ab9fd017f1ff23ce33201a0f701"1494224STANDARDdata/database/cpic_db_dump-v1.13_inserts.sql.gz2022-02-16T23:19:57.000Z"58678dbe9a70ce4e792a17b7b49c9033"1716433STANDARDdata/database/cpic_db_dump-v1.14.sql.gz2022-02-18T22:25:36.000Z"a70d5128401170e4c0018694e1fb797c"1460844STANDARDdata/database/cpic_db_dump-v1.14_inserts.sql.gz2022-02-18T22:25:37.000Z"6b0009851dda687c2b15fc0d9b9c7161"1681375STANDARDdata/database/cpic_db_dump-v1.15.1.sql.gz2022-03-11T19:42:11.000Z"2cb614bc8468c4f0bd1e38ef5243707d"1560823STANDARDdata/database/cpic_db_dump-v1.15.1_inserts.sql.gz2022-03-11T19:42:13.000Z"c9786962a1b72786cde8eef45fcf8fec"1786492STANDARDdata/database/cpic_db_dump-v1.16.sql.gz2022-03-28T15:57:25.000Z"64357802849c0d28c5ef1d2f5958db29"1608361STANDARDdata/database/cpic_db_dump-v1.16_inserts.sql.gz2022-03-28T15:57:26.000Z"20ae9676943f081da8d71e15e2c426b6"1832142STANDARDdata/database/cpic_db_dump-v1.17.sql.gz2022-04-20T21:25:52.000Z"a0dcbf0ae315ba539123dae5e6561155"1614816STANDARDdata/database/cpic_db_dump-v1.17_inserts.sql.gz2022-04-20T21:25:54.000Z"ec6b2d25f8c54ac93d2ce3cd94e9b211"1840459STANDARDdata/database/cpic_db_dump-v1.18.0.sql.gz2022-06-14T20:42:43.000Z"7e8cfa6faab2c3945a832cffcb223a3e"1629989STANDARDdata/database/cpic_db_dump-v1.18.0_inserts.sql.gz2022-06-14T20:42:22.000Z"5db63b2e14c86770fc8715918508a8c4"1856695STANDARDdata/database/cpic_db_dump-v1.19.0.sql.gz2022-08-21T03:11:23.000Z"6fc780c4f97907094599dead8ef3af52"1638853STANDARDdata/database/cpic_db_dump-v1.19.0_inserts.sql.gz2022-08-21T03:11:25.000Z"2c16e6b9d88b0c4728f9961e2aca3071"1865463STANDARDdata/database/cpic_db_dump-v1.19.1-2-g3f9bdd0.sql.gz2022-08-26T00:35:22.000Z"0538f9b5b0554a09c61610c06dca2cb0"1670403STANDARDdata/database/cpic_db_dump-v1.19.1-2-g3f9bdd0_inserts.sql.gz2022-08-26T00:35:23.000Z"36e87860bb868716280161570c315ac6"1897630STANDARDdata/database/cpic_db_dump-v1.19.1.sql.gz2022-08-25T19:56:21.000Z"e130844651b1f38c3c63c48ced75897b"1311729STANDARDdata/database/cpic_db_dump-v1.19.1_inserts.sql.gz2022-08-25T19:56:22.000Z"139251e8c4b52381d4dc1b251b898f9f"1515888STANDARDdata/database/cpic_db_dump-v1.2.sql.gz2021-03-26T02:54:27.000Z"993f6940ad1b8a5a4780004e5598fcaf"1287596STANDARDdata/database/cpic_db_dump-v1.20.0.sql.gz2022-09-15T01:25:16.000Z"4c66a4fe4789b483a0e631fc14ed3fcb"1866188STANDARDdata/database/cpic_db_dump-v1.20.0_inserts.sql.gz2022-09-15T01:25:17.000Z"1944b1f69c17bc935ca727f855538057"2099582STANDARDdata/database/cpic_db_dump-v1.21.0.sql.gz2022-10-05T17:21:43.000Z"97dce6cbed546f5aef6252e14c8c299a"1867123STANDARDdata/database/cpic_db_dump-v1.21.0_inserts.sql.gz2022-10-05T17:21:44.000Z"870c4e9340d28d37d9f8bf41551d8186"2101373STANDARDdata/database/cpic_db_dump-v1.21.1.sql.gz2022-10-20T23:25:16.000Z"e3d53f01f25555a2560749ef01e16a70"1825638STANDARDdata/database/cpic_db_dump-v1.21.1_inserts.sql.gz2022-10-20T23:25:17.000Z"5d8eddde1a97c1a0cc753a1876aa0116"2064110STANDARDdata/database/cpic_db_dump-v1.21.2.sql.gz2022-10-24T18:50:05.000Z"34e90de395f612ebc005fcb3947f0101"1432233STANDARDdata/database/cpic_db_dump-v1.21.2_inserts.sql.gz2022-10-24T18:50:06.000Z"a363eb5f493211bd92dab1694899e4d8"1651336STANDARDdata/database/cpic_db_dump-v1.21.3.sql.gz2022-10-31T22:18:53.000Z"c1e3aef29ef3b31df251a2a935cabe4d"1845253STANDARDdata/database/cpic_db_dump-v1.21.3_inserts.sql.gz2022-10-31T22:18:54.000Z"71a046e7f55a6061720a1fa5cac7e497"2085357STANDARDdata/database/cpic_db_dump-v1.21.4.sql.gz2022-12-20T02:06:01.000Z"9e5b043b8340e690d6163b40d41fed1f"1433787STANDARDdata/database/cpic_db_dump-v1.21.4_inserts.sql.gz2022-12-20T02:06:02.000Z"d52bef3459aa5e25fead46ad64cd064a"1657760STANDARDdata/database/cpic_db_dump-v1.21.5.sql.gz2022-12-20T02:17:33.000Z"607e3529ec49a2d7c105c1432d847aa5"1433938STANDARDdata/database/cpic_db_dump-v1.21.5_inserts.sql.gz2022-12-20T02:17:33.000Z"61475eac0a07fdd78386c8ee26d26c0e"1658581STANDARDdata/database/cpic_db_dump-v1.21.6.sql.gz2022-12-21T06:18:31.000Z"a3d9da19deb8705fdf86682a89a1355a"1853038STANDARDdata/database/cpic_db_dump-v1.21.6_inserts.sql.gz2022-12-21T06:18:33.000Z"75b16de4515b7cdcf28d7e239d22cc0a"2096207STANDARDdata/database/cpic_db_dump-v1.22.0.sql.gz2023-01-27T05:08:23.000Z"e5c61b10323bf9139092e2f46d46cb4f"1864583STANDARDdata/database/cpic_db_dump-v1.22.0_inserts.sql.gz2023-01-27T05:08:25.000Z"a243ca7d6dc12b7e0ff2beceb433ad96"2106499STANDARDdata/database/cpic_db_dump-v1.22.1.sql.gz2023-01-31T20:19:56.000Z"69b4f8173bbc9f995673251cebed84f1"1870801STANDARDdata/database/cpic_db_dump-v1.22.1_inserts.sql.gz2023-01-31T20:19:58.000Z"782eeb7b8bd20835e8e6078de2882d8c"2112794STANDARDdata/database/cpic_db_dump-v1.22.2.sql.gz2023-02-03T19:04:26.000Z"d3eda4a45e670edefe9a4981173971e3"1438291STANDARDdata/database/cpic_db_dump-v1.22.2_inserts.sql.gz2023-02-03T19:04:26.000Z"d3927b22ad6df49b5fd5b11762be9c0d"1661619STANDARDdata/database/cpic_db_dump-v1.23.0.sql.gz2023-02-28T04:03:15.000Z"62ac07514c52b038e369cff7571252db"1896626STANDARDdata/database/cpic_db_dump-v1.23.0_inserts.sql.gz2023-02-28T04:03:17.000Z"4422cc50a2747bab759d8456e10563b1"2144103STANDARDdata/database/cpic_db_dump-v1.23.1.sql.gz2023-03-10T04:21:26.000Z"a6fa773dc09c36ba1d98a289645d8bff"2019297STANDARDdata/database/cpic_db_dump-v1.23.1_inserts.sql.gz2023-03-10T04:21:28.000Z"558d34d76206b491ccd4363a705cfb5f"2276604STANDARDdata/database/cpic_db_dump-v1.24.0.sql.gz2023-03-23T19:27:45.000Z"4fe97784e7232340a63c5f10f63b0930"1993853STANDARDdata/database/cpic_db_dump-v1.24.0_inserts.sql.gz2023-03-23T19:27:46.000Z"6cf38b00c613a0e392515dcace93b316"2250752STANDARDdata/database/cpic_db_dump-v1.25.0.sql.gz2023-06-06T03:46:10.000Z"37659e5fe43c88bb6388d51f0d1d453f"2054669STANDARDdata/database/cpic_db_dump-v1.25.0_inserts.sql.gz2023-06-06T03:46:12.000Z"aa31cf24f7fe5e508a5392779dd1a9d8"2318952STANDARDdata/database/cpic_db_dump-v1.26.0.sql.gz2023-06-06T03:47:02.000Z"09c335b68febbb11a9e776ac7c7245e0"2054669STANDARDdata/database/cpic_db_dump-v1.26.0_inserts.sql.gz2023-06-06T03:47:04.000Z"872215f5227cc01d76570b1722ed3256"2318952STANDARDdata/database/cpic_db_dump-v1.27.0.sql.gz2023-07-13T04:00:22.000Z"a2206a9796512c77ba67b298b66509b6"2064818STANDARDdata/database/cpic_db_dump-v1.27.0_inserts.sql.gz2023-07-13T04:00:24.000Z"e4466a1034b8ea5b7eead7330c2565b0"2328147STANDARDdata/database/cpic_db_dump-v1.28.0.sql.gz2023-07-14T03:03:38.000Z"99ead41e0f69239b22c565aa80a49ba6"2072484STANDARDdata/database/cpic_db_dump-v1.28.0_inserts.sql.gz2023-07-14T03:03:40.000Z"35bb21324414abc8ebfb3d9306938314"2341816STANDARDdata/database/cpic_db_dump-v1.29.0.sql.gz2023-08-01T20:46:12.000Z"11059e4abda87f134333a0bc68e093d7"2091971STANDARDdata/database/cpic_db_dump-v1.29.0_inserts.sql.gz2023-08-01T20:46:14.000Z"1d3ea2aa6ad7c7ca537e9e3a2f81ee06"2360552STANDARDdata/database/cpic_db_dump-v1.2_inserts.sql.gz2021-03-26T02:54:29.000Z"92e7c0af5f3185495c136eaa23b541a1"1482969STANDARDdata/database/cpic_db_dump-v1.3.sql.gz2021-04-15T20:53:34.000Z"2458d5fad97dae5aaadb674b79933d93"1290405STANDARDdata/database/cpic_db_dump-v1.30.0.sql.gz2023-08-07T17:11:58.000Z"0cbad6aeedf43d12998a508151613c14"2096932STANDARDdata/database/cpic_db_dump-v1.30.0_inserts.sql.gz2023-08-07T17:12:00.000Z"b244643bcd4914289bfaf76865dd8757"2363005STANDARDdata/database/cpic_db_dump-v1.31.0.sql.gz2023-09-01T22:03:26.000Z"ee518f6359acb332b0c03bfdcc377fb2"2101949STANDARDdata/database/cpic_db_dump-v1.31.0_inserts.sql.gz2023-09-01T22:03:27.000Z"240b2cb4cc589fa30bbdcbfc81961484"2370238STANDARDdata/database/cpic_db_dump-v1.31.1.sql.gz2023-09-27T04:54:43.000Z"07a981bac9d6ebfcb3e249fe9d7dee54"2125392STANDARDdata/database/cpic_db_dump-v1.31.1_inserts.sql.gz2023-09-27T04:54:45.000Z"68a59a36c3d0f84ec10e82c0dc8c0936"2395465STANDARDdata/database/cpic_db_dump-v1.32.0.sql.gz2023-10-03T03:11:14.000Z"b09f52ab49c96178b4eb1b6a56c68e4a"2141686STANDARDdata/database/cpic_db_dump-v1.32.0_inserts.sql.gz2023-10-03T03:11:15.000Z"ac6f1d75ff3562081990b48702364b6f"2410192STANDARDdata/database/cpic_db_dump-v1.33.0.sql.gz2023-10-24T19:24:03.000Z"fe5dd514c8ca519ff8319017284863b1"2149666STANDARDdata/database/cpic_db_dump-v1.33.0_inserts.sql.gz2023-10-24T19:24:05.000Z"e7731798f5b88ab8bbb18dd269613552"2420001STANDARDdata/database/cpic_db_dump-v1.34.0.sql.gz2023-12-15T22:28:17.000Z"9471fe83e584719f9c80884cc2ea4024"2870785STANDARDdata/database/cpic_db_dump-v1.34.0_inserts.sql.gz2023-12-15T22:28:19.000Z"22b0dd300095213ee40a5e1621353ae1"3262536STANDARDdata/database/cpic_db_dump-v1.35.0.sql.gz2023-12-18T20:02:41.000Z"3d9cc2bff6c694beace8039fb35c0645"2856531STANDARDdata/database/cpic_db_dump-v1.35.0_inserts.sql.gz2023-12-18T20:02:30.000Z"84779510909deb3cfd9f019a85734e5e"3240097STANDARDdata/database/cpic_db_dump-v1.36.0.sql.gz2023-12-21T19:42:50.000Z"03e86d622b6f5726905754d9c90e65ee"2905732STANDARDdata/database/cpic_db_dump-v1.36.0_inserts.sql.gz2023-12-21T19:42:51.000Z"f3cfe1a4ad7949f6a8b4110c538b9ee2"3308555STANDARDdata/database/cpic_db_dump-v1.37.0.sql.gz2024-01-13T05:30:41.000Z"69dba4eb6f02d79d7df224e7283c6ef3"2872926STANDARDdata/database/cpic_db_dump-v1.37.0_inserts.sql.gz2024-01-13T05:30:42.000Z"06a5f8de08801d9d889a36811a2028d6"3260340STANDARDdata/database/cpic_db_dump-v1.38.0.sql.gz2024-02-15T17:33:44.000Z"d734fc592c5cb905bc387b00359c02d6"3176804STANDARDdata/database/cpic_db_dump-v1.38.0_inserts.sql.gz2024-02-15T17:33:46.000Z"b95b0f8dd43e8cac5a14a66a45d7ff59"3616596STANDARDdata/database/cpic_db_dump-v1.39.0.sql.gz2024-03-28T20:35:20.000Z"48f3d231ff6f806c780c1c1014aa20d3"3192497STANDARDdata/database/cpic_db_dump-v1.39.0_inserts.sql.gz2024-03-28T20:35:23.000Z"610641399fdcfd3cce98ccb9365e964d"3636161STANDARDdata/database/cpic_db_dump-v1.3_inserts.sql.gz2021-04-15T20:53:36.000Z"d1c0dd2d80e655178c8779c3765c24fd"1484569STANDARDdata/database/cpic_db_dump-v1.4.sql.gz2021-05-06T00:28:25.000Z"35dc9700af86e645200bd3454d2967ad"1293416STANDARDdata/database/cpic_db_dump-v1.40.0.sql.gz2024-06-24T18:01:28.000Z"9cd3371094d66a43933a61b3e33c593e"3197509STANDARDdata/database/cpic_db_dump-v1.40.0_inserts.sql.gz2024-06-24T18:01:28.000Z"f2ec76224e42fea5b6ebd59b35f42a0e"3647152STANDARDdata/database/cpic_db_dump-v1.40.1.sql.gz2024-07-11T21:55:44.000Z"3d015819974ea939d70bd05263786ece"3201347STANDARDdata/database/cpic_db_dump-v1.40.1_inserts.sql.gz2024-07-11T21:55:46.000Z"fbfa7e36cce4aa9d41f50611c4bd20e1"3650870STANDARDdata/database/cpic_db_dump-v1.41.0.sql.gz2024-07-25T23:09:10.000Z"f09e689c290ec9cff2a7eafea048238b"3230756STANDARDdata/database/cpic_db_dump-v1.41.0_inserts.sql.gz2024-07-25T23:09:13.000Z"ddaf8f81e00db53fc8aec9a9c0d9f086"3684791STANDARDdata/database/cpic_db_dump-v1.42.0.sql.gz2024-10-03T22:19:30.000Z"349a9797d0c8340e63766ad5d0ba33da"3246376STANDARDdata/database/cpic_db_dump-v1.42.0_inserts.sql.gz2024-10-03T22:19:33.000Z"4b76d4e67d559e4cf9ab9e57b57e6b05"3699476STANDARDdata/database/cpic_db_dump-v1.42.1.sql.gz2024-10-16T18:13:14.000Z"fa97db0536dcd5cfb4340e68ca923abf"3257287STANDARDdata/database/cpic_db_dump-v1.42.1_inserts.sql.gz2024-10-16T18:13:17.000Z"21fb221f6feba6c9ba11fcd676970d60"3706937STANDARDdata/database/cpic_db_dump-v1.42.2.sql.gz2024-10-16T23:22:37.000Z"bea4b448a7bd4770986076f15d020cd5"3277196STANDARDdata/database/cpic_db_dump-v1.42.2_inserts.sql.gz2024-10-16T23:22:40.000Z"014e1fb6a4ca20b0bdb81fabeaba2d90"3732895STANDARDdata/database/cpic_db_dump-v1.42.3.sql.gz2024-10-18T16:58:57.000Z"ebafe9f3e1646cb1c391763cd52049a8"3294493STANDARDdata/database/cpic_db_dump-v1.42.3_inserts.sql.gz2024-10-18T16:59:00.000Z"1f9554324df6440f4bc06eac80c29e3d"3757822STANDARDdata/database/cpic_db_dump-v1.43.0.sql.gz2024-11-05T21:23:41.000Z"29b39df9be82f3b70a632745e79f5d75"3275220STANDARDdata/database/cpic_db_dump-v1.43.0_inserts.sql.gz2024-11-05T21:23:44.000Z"91ea59a1fc09ca48172a400823bedb6a"3726282STANDARDdata/database/cpic_db_dump-v1.44.0.sql.gz2025-03-08T00:29:15.000Z"6ebbb7914d7e757138fff736f64c5f79"CRC64NVMEFULL_OBJECT3250038STANDARDdata/database/cpic_db_dump-v1.44.0_inserts.sql.gz2025-03-08T00:29:17.000Z"501a48c54ad79c180616fe5220f31aa1"CRC64NVMEFULL_OBJECT3696983STANDARDdata/database/cpic_db_dump-v1.45.0-1-g41556df.sql.gz2025-05-30T17:56:03.000Z"eda47bdaf0ea86ce48e11acb8f5db7a5"CRC64NVMEFULL_OBJECT3325431STANDARDdata/database/cpic_db_dump-v1.45.0-1-g41556df_inserts.sql.gz2025-05-30T17:56:06.000Z"fa53915c60a0d13349b339d6fa2a888a"CRC64NVMEFULL_OBJECT3791078STANDARDdata/database/cpic_db_dump-v1.45.0.sql.gz2025-05-14T22:38:23.000Z"04d30d4d38d9f027931b98befd653305"CRC64NVMEFULL_OBJECT3311553STANDARDdata/database/cpic_db_dump-v1.45.0_inserts.sql.gz2025-05-14T22:38:26.000Z"138b69e5704799f6a898e7caabf64357"CRC64NVMEFULL_OBJECT3763706STANDARDdata/database/cpic_db_dump-v1.46.0.sql.gz2025-05-30T18:08:49.000Z"d0ed47ffe7a37f3442b51105228f344a"CRC64NVMEFULL_OBJECT3325420STANDARDdata/database/cpic_db_dump-v1.46.0_inserts.sql.gz2025-05-30T18:08:52.000Z"274fc7368da01149595aefa4838cdad3"CRC64NVMEFULL_OBJECT3791067STANDARDdata/database/cpic_db_dump-v1.47.0.sql.gz2025-06-17T05:24:53.000Z"8da53e93e082996483a2b6f4cc03aa30"CRC64NVMEFULL_OBJECT3325441STANDARDdata/database/cpic_db_dump-v1.47.0_inserts.sql.gz2025-06-17T05:24:55.000Z"6b908dcd81de8c621ef94a748e722fb0"CRC64NVMEFULL_OBJECT3782438STANDARDdata/database/cpic_db_dump-v1.48.0.sql.gz2025-08-13T20:08:35.000Z"6c4c54da1d38cd8ea03da02abd4d8ccd"CRC64NVMEFULL_OBJECT3335572STANDARDdata/database/cpic_db_dump-v1.48.0_inserts.sql.gz2025-08-13T20:08:37.000Z"1dc752099cdf65349ef44098885ffb7a"CRC64NVMEFULL_OBJECT3794178STANDARDdata/database/cpic_db_dump-v1.49.0.sql.gz2025-08-21T20:23:20.000Z"b7e6c784d0a4d4d745d25c8840954a08"CRC64NVMEFULL_OBJECT3335336STANDARDdata/database/cpic_db_dump-v1.49.0_inserts.sql.gz2025-08-21T20:23:23.000Z"b3eb21af1478d4b4e4ffef72c1e72406"CRC64NVMEFULL_OBJECT3793920STANDARDdata/database/cpic_db_dump-v1.4_inserts.sql.gz2021-05-06T00:28:27.000Z"b2da3969517df4e4129402a1dc30168b"1488665STANDARDdata/database/cpic_db_dump-v1.5.sql.gz2021-05-28T17:59:28.000Z"17ca860065be6d9d20d71b8045d4dade"1312322STANDARDdata/database/cpic_db_dump-v1.50.0.sql.gz2025-08-26T19:00:21.000Z"a88922754849821331e294533afdc3a6"CRC64NVMEFULL_OBJECT3407350STANDARDdata/database/cpic_db_dump-v1.50.0_inserts.sql.gz2025-08-26T19:00:24.000Z"6bcfdd63ec84d9557518daf1efc73ed4"CRC64NVMEFULL_OBJECT3873454STANDARDdata/database/cpic_db_dump-v1.51.0-1-g584329c.sql.gz2025-09-26T04:17:00.000Z"3359bf5645d9eea32f34a30e3c957400"CRC64NVMEFULL_OBJECT3501765STANDARDdata/database/cpic_db_dump-v1.51.0-1-g584329c_inserts.sql.gz2025-09-26T04:17:02.000Z"d686ad1dce3658f922f9c42939a2ac79"CRC64NVMEFULL_OBJECT3995064STANDARDdata/database/cpic_db_dump-v1.51.0.sql.gz2025-09-16T22:33:51.000Z"e974a9b434e8b305a8d803f2b7c3dd31"CRC64NVMEFULL_OBJECT3453467STANDARDdata/database/cpic_db_dump-v1.51.0_inserts.sql.gz2025-09-16T22:33:53.000Z"b6f834767b5d72f81010458b59f486ea"CRC64NVMEFULL_OBJECT3934091STANDARDdata/database/cpic_db_dump-v1.52.0.sql.gz2025-09-26T04:29:07.000Z"face5da372ef6cf7900038e564709f44"CRC64NVMEFULL_OBJECT3501751STANDARDdata/database/cpic_db_dump-v1.52.0_inserts.sql.gz2025-09-26T04:29:09.000Z"5cbd3579696af3b183f9b42f2b2a598a"CRC64NVMEFULL_OBJECT3995052STANDARDdata/database/cpic_db_dump-v1.53.0.sql.gz2025-10-20T17:29:13.000Z"a37410304f8c664d415432378ca5dab5"CRC64NVMEFULL_OBJECT3481826STANDARDdata/database/cpic_db_dump-v1.53.0_inserts.sql.gz2025-10-20T17:29:16.000Z"ead1a69a14de3532451a16cd787732fe"CRC64NVMEFULL_OBJECT3956323STANDARDdata/database/cpic_db_dump-v1.53.1.sql.gz2025-10-27T20:54:51.000Z"5de916f6b5980cc7949391c624a4f57d"CRC64NVMEFULL_OBJECT3491571STANDARDdata/database/cpic_db_dump-v1.53.1_inserts.sql.gz2025-10-27T20:54:53.000Z"0549b3883b0133b01ecad5760a74755b"CRC64NVMEFULL_OBJECT3972903STANDARDdata/database/cpic_db_dump-v1.53.2.sql.gz2025-10-28T04:23:08.000Z"629575951b12d4c096c165a862c5d651"CRC64NVMEFULL_OBJECT3554225STANDARDdata/database/cpic_db_dump-v1.53.2_inserts.sql.gz2025-10-28T04:23:11.000Z"95fe32596d92251b53e424a3179e221a"CRC64NVMEFULL_OBJECT4045683STANDARDdata/database/cpic_db_dump-v1.54.0-2-gc26148d.sql.gz2026-02-05T23:43:55.000Z"2f0d112b3a15f7f53e1b0c7e47c1d9e5"CRC64NVMEFULL_OBJECT3551912STANDARDdata/database/cpic_db_dump-v1.54.0-2-gc26148d_inserts.sql.gz2026-02-05T23:43:57.000Z"485ae4239ce019be8ea68e729a89a647"CRC64NVMEFULL_OBJECT4034759STANDARDdata/database/cpic_db_dump-v1.54.0.sql.gz2026-02-04T18:59:21.000Z"3b7ae6fb52f40e3c03bce3c0a9b96074"CRC64NVMEFULL_OBJECT3549920STANDARDdata/database/cpic_db_dump-v1.54.0_inserts.sql.gz2026-02-04T18:59:23.000Z"9e3556b8e02a6faff8a3d9e1f3b0b8d3"CRC64NVMEFULL_OBJECT4032640STANDARDdata/database/cpic_db_dump-v1.55.0.sql.gz2026-03-13T20:08:22.000Z"364a8e613847bff68bbc4094bda5fbe1"CRC64NVMEFULL_OBJECT3557017STANDARDdata/database/cpic_db_dump-v1.55.0_inserts.sql.gz2026-03-13T20:08:25.000Z"6bac1aa1c9297165088d314b3d705394"CRC64NVMEFULL_OBJECT4039573STANDARDdata/database/cpic_db_dump-v1.5_inserts.sql.gz2021-05-28T17:59:29.000Z"d70d22c22f472127b20ba843b6ca11c1"1509000STANDARDdata/database/cpic_db_dump-v1.6.sql.gz2021-06-14T05:42:07.000Z"e970ecf65a4f31918ac2df10929382b3"1326526STANDARDdata/database/cpic_db_dump-v1.6_inserts.sql.gz2021-06-14T05:42:09.000Z"66d6d771b5091cdcc59cfa845690c6cc"1527155STANDARDdata/database/cpic_db_dump-v1.7.sql.gz2021-07-09T21:40:48.000Z"9fa21e2813ac473041d1ae3fe12975db"1339018STANDARDdata/database/cpic_db_dump-v1.7_inserts.sql.gz2021-07-09T21:40:49.000Z"a2ee7e948df02bae67160e2c97e5e4ad"1541451STANDARDdata/database/cpic_db_dump-v1.8.sql.gz2021-08-18T22:24:36.000Z"48135dd17df01d8af71e048a7c606398"1354002STANDARDdata/database/cpic_db_dump-v1.8_inserts.sql.gz2021-08-18T22:24:38.000Z"61fc68fa1259e99fff356ab9254b47a7"1556912STANDARDdata/database/cpic_db_dump-v1.9.sql.gz2021-09-09T21:11:12.000Z"c9edbfedd35ce0ef0bb4a9852f9ab3c6"1368976STANDARDdata/database/cpic_db_dump-v1.9_inserts.sql.gz2021-09-09T21:11:14.000Z"24880d0bf060dcef4be00b38f58ff3e2"1573177STANDARDdata/database/cpic_db_dump.sql.gz2026-03-13T20:08:23.000Z"364a8e613847bff68bbc4094bda5fbe1"CRC64NVMEFULL_OBJECT3557017STANDARDdata/gene/2020-10-07T20:14:06.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/gene/CYP2D6/2020-10-07T20:14:11.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx2020-10-07T20:14:45.000Z"9af0f12160517d99410c4b0b746e3d58"14830STANDARDdata/guideline/2019-02-13T01:38:59.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/2019-02-13T01:39:09.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/G6PD/2022-09-14T23:28:48.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/G6PD/2022/2022-09-14T23:28:49.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/G6PD/2022/36049896-supplement.pdf2023-06-22T20:36:13.000Z"c6084d35f9734f5c219735d9f9fd7d7c"725209STANDARDdata/guideline/publication/G6PD/2022/36049896.pdf2023-06-22T20:36:13.000Z"2d4d2035b5e510f39127516633a325cc"275489STANDARDdata/guideline/publication/NSAID/2021-05-06T17:35:48.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/NSAID/2020/2021-05-06T17:35:48.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/NSAID/2020/32189324-supplement.pdf2023-04-10T17:59:19.000Z"6d34e90c53441062f72f26e7e60ec6b9"2552036STANDARDdata/guideline/publication/NSAID/2020/32189324.pdf2023-04-10T17:59:19.000Z"b50d6122f7710366be133258de8e3e30"260975STANDARDdata/guideline/publication/NSAID/2020/CPIC_NSAID_PREPRINT.pdf2021-05-06T17:35:51.000Z"aa5b312b70276ad7725272c57c6247f5"1137838STANDARDdata/guideline/publication/NSAID/2020/CPIC_NSAID_PREPRINT_supplement.pdf2021-05-06T17:35:49.000Z"7b77124966ae791d636827a8f289f091"2441855STANDARDdata/guideline/publication/NSAID/Celecoxib_Drug_Resource_Mappings.xlsx2023-04-10T17:59:19.000Z"de97916d815914215140a2559e8c353d"9428STANDARDdata/guideline/publication/NSAID/Celecoxib_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2023-06-22T20:36:13.000Z"318716e984f9ed3a70b5c5f6b54e43c6"52499STANDARDdata/guideline/publication/NSAID/Diclofenac_Drug_Resource_Mappings.xlsx2023-04-10T17:59:19.000Z"b8bd2132581c9821a59501465c182067"9441STANDARDdata/guideline/publication/NSAID/Flurbiprofen_Drug_Resource_Mappings.xlsx2023-04-10T17:59:19.000Z"d58d37b0757872520adad4867b745e4b"9451STANDARDdata/guideline/publication/NSAID/Flurbiprofen_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2023-06-22T20:36:13.000Z"d36217c3fc15bcced9d20ee83c6a80d1"52736STANDARDdata/guideline/publication/NSAID/Ibuprofen_Drug_Resource_Mappings.xlsx2023-04-10T17:59:19.000Z"19e021e3126970f12a6b129373bbb00e"9443STANDARDdata/guideline/publication/NSAID/Ibuprofen_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2023-06-22T20:36:13.000Z"5208ad663b51f707952364a323d84911"53354STANDARDdata/guideline/publication/NSAID/Lornoxicam_Drug_Resource_Mappings.xlsx2023-04-10T17:59:19.000Z"d12366fb6c552285b300c8fb6dff95ec"9425STANDARDdata/guideline/publication/NSAID/Lornoxicam_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2023-06-22T20:36:13.000Z"38ee1cecacb52756b9030039dc0907bc"53454STANDARDdata/guideline/publication/NSAID/Meloxicam_Drug_Resource_Mappings.xlsx2023-04-10T17:59:19.000Z"f624eca7bbccec265c791199f4f1437a"9432STANDARDdata/guideline/publication/NSAID/Meloxicam_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2023-04-10T17:59:19.000Z"94a8b6b9c5ce4b811080e8547196b551"54348STANDARDdata/guideline/publication/NSAID/Naproxen_Drug_Resource_Mappings.xlsx2023-04-10T17:59:19.000Z"a226a52d1736edcddd65c88f4c9bd6f9"9444STANDARDdata/guideline/publication/NSAID/Piroxicam_Drug_Resource_Mappings.xlsx2023-04-10T17:59:19.000Z"216ce7ff556390d9380a625058484e11"9446STANDARDdata/guideline/publication/NSAID/Piroxicam_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2023-04-10T17:59:20.000Z"15d967e7b6802c6af68ed17a19921668"52737STANDARDdata/guideline/publication/NSAID/Tenoxicam_Drug_Resource_Mappings.xlsx2023-04-10T17:59:20.000Z"b27f147272b58cf6372acc9c27e8a229"9440STANDARDdata/guideline/publication/NSAID/Tenoxicam_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2023-04-10T17:59:20.000Z"71edc827ee56d461aa2b2263051852ad"52731STANDARDdata/guideline/publication/PPI/2021-05-06T17:36:00.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/PPI/2020/2021-05-06T17:36:15.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/PPI/2020/32770672-supplement.pdf2023-04-10T17:59:20.000Z"9c648fb7025aa9af79eb6b54b66a32fc"775271STANDARDdata/guideline/publication/PPI/2020/32770672.pdf2023-04-10T17:59:20.000Z"9a0c2cb77dda71ed21017ab450a385e1"218956STANDARDdata/guideline/publication/PPI/2020/CYP2C19_proton_pump_inhibitors_guideline_revised.pdf2021-05-06T17:36:15.000Z"c952ca651f27e9d617fd3b8abc917fd4"310009STANDARDdata/guideline/publication/PPI/2020/CYP2C19_proton_pump_inhibitors_guideline_supp_revised.pdf2021-05-06T17:36:15.000Z"d9d1cf85704d92aff82cd14fa9b7e386"775365STANDARDdata/guideline/publication/PPI/Dexlansoprazole-Drug_Resource_Mappings.xlsx2023-04-10T17:59:20.000Z"eee7d1e67aeb1599202642a205d7d43d"8993STANDARDdata/guideline/publication/PPI/Dexlansoprazole_Pre_and_Post_Test_Alerts.xlsx2023-04-10T17:59:20.000Z"83ef274bb143fabe6e8e0212a633ab3c"57952STANDARDdata/guideline/publication/PPI/Lansoprazole-Drug_Resource_Mappings.xlsx2023-04-10T17:59:20.000Z"1ed642231c781026fe3d9294dcd61248"3902STANDARDdata/guideline/publication/PPI/Lansoprazole_Pre_and_Post_Test_Alerts.xlsx2023-04-10T17:59:20.000Z"52d8dbbfc103edf548bd5b96aa7eb62a"57432STANDARDdata/guideline/publication/PPI/Omeprazole-Drug_Resource_Mappings.xlsx2023-04-10T17:59:20.000Z"0f839f96b98e289ddadf9d6b2af87bf4"3900STANDARDdata/guideline/publication/PPI/Omeprazole_Pre_and_Post_Test_Alerts.xlsx2023-04-10T17:59:21.000Z"76e3f863a3374278d3048b81f660f837"57513STANDARDdata/guideline/publication/PPI/Pantoprazole-Drug_Resource_Mappings.xlsx2023-04-10T17:59:21.000Z"8d79c4e9da0de010e9c8cd835355c760"3902STANDARDdata/guideline/publication/PPI/Pantoprazole_Pre_and_Post_Test_Alerts.xlsx2023-04-10T17:59:21.000Z"fdbe81de3b0ade8067216acab6c01cef"57513STANDARDdata/guideline/publication/SSRI/2021-05-06T17:36:19.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/SSRI/2015/2021-05-06T17:36:22.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/SSRI/2015/25974703-supplement.pdf2023-04-10T17:59:21.000Z"653c5555d8e978590c656ad5053ae2ec"1922259STANDARDdata/guideline/publication/SSRI/2015/25974703.pdf2023-04-10T17:59:21.000Z"dad20250808eeddefac97463a11ab370"161671STANDARDdata/guideline/publication/SSRI/2015/25974703_2015_CYP2C19_SSRI_translation_table.xlsx2023-04-10T17:59:22.000Z"e6266300324fe534fe4955eef5ec6a35"65434STANDARDdata/guideline/publication/SSRI/2015/25974703_2015_CYP2D6_SSRI_translation_table.xlsx2023-04-10T17:59:22.000Z"5716a3e1c5c336aed96f71fe88759703"226527STANDARDdata/guideline/publication/SSRI/2015/25974703_CYP2C19_frequency_table.xlsx2023-04-10T17:59:22.000Z"19e5e965ca1c57628f522d568ae5a9c2"250334STANDARDdata/guideline/publication/SSRI/2015/25974703_CYP2C19_frequency_table_legend.pdf2023-04-10T17:59:22.000Z"f0270e7c1fe1b24ac573cb12a0be77e6"166315STANDARDdata/guideline/publication/SSRI/2015/25974703_CYP2D6_frequency_table_(R3).xlsx2023-04-10T17:59:22.000Z"4da4ed69642509b9e54fb33ad661c22d"350402STANDARDdata/guideline/publication/SSRI/2015/25974703_CYP2D6_frequency_table_legend_(R3).pdf2023-04-10T17:59:23.000Z"e3d3b483e0e11f25c36f77d534ff88e3"145569STANDARDdata/guideline/publication/SSRI/2015/Citalopram_Drug_Resource_Mappings.xlsx2021-05-06T17:36:26.000Z"9e9f588c6fe6ac8544ad7b8ab510383b"8782STANDARDdata/guideline/publication/SSRI/2015/Citalopram_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2021-05-06T17:36:26.000Z"d3d6e2f09e1b6f4231db3cc5aab8d440"15692STANDARDdata/guideline/publication/SSRI/2015/Escitalopram_Drug_Resource_Mappings.xlsx2021-05-06T17:36:26.000Z"d4069af47eb461c45444a11afc823689"8815STANDARDdata/guideline/publication/SSRI/2015/Escitalopram_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2021-05-06T17:36:26.000Z"0af6b1e56f87b1a15f3f82e78455e8c3"15730STANDARDdata/guideline/publication/SSRI/2015/Fluvoxamine_Drug_Resource_Mappings.xlsx2021-05-06T17:36:26.000Z"e38281a37b1baae6ecca2339ba21363e"8816STANDARDdata/guideline/publication/SSRI/2015/Fluvoxamine_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2021-05-06T17:36:27.000Z"02cd82d25993d434ab7dbfcd7b03a39e"15575STANDARDdata/guideline/publication/SSRI/2015/Paroxetine_Drug_Resource_Mappings.xlsx2021-05-06T17:36:27.000Z"60f211b4218cc349d7e153ef33b63bd2"8808STANDARDdata/guideline/publication/SSRI/2015/Paroxetine_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2021-05-06T17:36:27.000Z"f947e97726bcefd3a3deb48541094127"15730STANDARDdata/guideline/publication/SSRI/2015/Sertraline_Drug_Resource_Mappings.xlsx2021-05-06T17:36:27.000Z"2a84dea2c49d40ea568881f7f2dfd66b"8812STANDARDdata/guideline/publication/SSRI/2015/Sertraline_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2021-05-06T17:36:27.000Z"6967c10991fe428115afd6ff280a46a8"15650STANDARDdata/guideline/publication/SSRI/Citalopram_Drug_Resource_Mappings.xlsx2023-04-10T17:59:24.000Z"c8c7d452f6471daf0a0f6c0e535204a2"37474STANDARDdata/guideline/publication/SSRI/Citalopram_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2023-04-10T17:59:24.000Z"d3d6e2f09e1b6f4231db3cc5aab8d440"15692STANDARDdata/guideline/publication/SSRI/Escitalopram_Drug_Resource_Mappings.xlsx2023-04-10T17:59:24.000Z"0f25f443b834c5b163edf82ff404e4a1"37885STANDARDdata/guideline/publication/SSRI/Escitalopram_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2023-04-10T17:59:25.000Z"0af6b1e56f87b1a15f3f82e78455e8c3"15730STANDARDdata/guideline/publication/SSRI/Fluvoxamine_Drug_Resource_Mappings.xlsx2023-04-10T17:59:25.000Z"096c77447f45b03619dd7802130b89c5"37501STANDARDdata/guideline/publication/SSRI/Fluvoxamine_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2023-04-10T17:59:25.000Z"02cd82d25993d434ab7dbfcd7b03a39e"15575STANDARDdata/guideline/publication/SSRI/Paroxetine_Drug_Resource_Mappings.xlsx2023-04-10T17:59:25.000Z"359b95cfcbab0f2bbfb461ff32bf2676"32383STANDARDdata/guideline/publication/SSRI/Paroxetine_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2023-04-10T17:59:25.000Z"f947e97726bcefd3a3deb48541094127"15730STANDARDdata/guideline/publication/SSRI/Sertraline_Drug_Resource_Mappings.xlsx2023-04-10T17:59:25.000Z"794d951b6b1b8988da83f2ad82501b3d"31941STANDARDdata/guideline/publication/SSRI/Sertraline_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2023-04-10T17:59:25.000Z"6967c10991fe428115afd6ff280a46a8"15650STANDARDdata/guideline/publication/TCA/2021-05-06T17:36:28.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/TCA/2013/2021-05-06T17:36:31.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/TCA/2013/23486447-CYP2D6_frequency_table_(R2).xlsx2023-04-10T17:59:25.000Z"3c140b33a01dc29b99cb3e3f719c8a70"301730STANDARDdata/guideline/publication/TCA/2013/23486447-CYP2D6_frequency_table_legend_(R2).pdf2023-04-10T17:59:25.000Z"4913c240187e606dd1e54abc68e010bf"1022027STANDARDdata/guideline/publication/TCA/2013/23486447-supplement.pdf2023-04-10T17:59:25.000Z"e2cb8639dd2c60b1fe499d191d1eb04f"834466STANDARDdata/guideline/publication/TCA/2013/23486447.pdf2023-04-10T17:59:25.000Z"0fa0bc555006c6c1a7fa230515fc2558"240488STANDARDdata/guideline/publication/TCA/2016/2021-05-06T17:36:31.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/TCA/2016/27997040-supplement.pdf2023-04-10T17:59:25.000Z"04aaa554633a6aecfee692ca829d62d4"873604STANDARDdata/guideline/publication/TCA/2016/27997040.pdf2023-04-10T17:59:26.000Z"c53105218a737f14c73bc4b262258096"219839STANDARDdata/guideline/publication/TCA/2016/Amitriptyline_Drug_Resource_Mappings.xlsx2023-04-10T17:59:27.000Z"bc7dcc6980d672a0ed919761e3e3f023"8831STANDARDdata/guideline/publication/TCA/2016/Amitriptyline_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2023-04-10T17:59:27.000Z"dd05ca6164107363c98076620d76d805"371296STANDARDdata/guideline/publication/TCA/2016/Clomipramine_Drug_Resource_Mappings.xlsx2023-04-10T17:59:29.000Z"490b6f8b4583ef6da0a590ab6522e12a"29877STANDARDdata/guideline/publication/TCA/2016/Desipramine_Drug_Resource_Mappings.xlsx2023-04-10T17:59:29.000Z"49acd6dde2421a82d7eb9e4958de2398"28897STANDARDdata/guideline/publication/TCA/2016/Doxepin_Drug_Resource_Mappings.xlsx2023-04-10T17:59:30.000Z"8ffd4228b8c78794115e7c74b668a340"34596STANDARDdata/guideline/publication/TCA/2016/Imipramine_Drug_Resource_Mappings.xlsx2023-04-10T17:59:30.000Z"e5409d2f3b9686a9922a955f7b342bb0"34012STANDARDdata/guideline/publication/TCA/2016/Nortriptyline_Drug_Resource_Mappings.xlsx2023-04-10T17:59:30.000Z"203d785215d275afe3789967db1743d5"8815STANDARDdata/guideline/publication/TCA/2016/Nortriptyline_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2023-04-10T17:59:30.000Z"d36bca6801965a554b0a82a132be88e5"89838STANDARDdata/guideline/publication/TCA/2016/TCA_2016.pdf2021-05-06T17:36:35.000Z"c53105218a737f14c73bc4b262258096"219839STANDARDdata/guideline/publication/TCA/2016/TCA_Supplement_2016.pdf2021-05-06T17:36:36.000Z"04aaa554633a6aecfee692ca829d62d4"873604STANDARDdata/guideline/publication/TCA/2016/Trimipramine_Drug_Resource_Mappings.xlsx2023-04-10T17:59:30.000Z"f96b681a1e92a42103c8bcc51bd0b7cc"34453STANDARDdata/guideline/publication/TCA/Amitriptyline_Drug_Resource_Mappings.xlsx2023-04-10T17:59:30.000Z"bc7dcc6980d672a0ed919761e3e3f023"8831STANDARDdata/guideline/publication/TCA/Clomipramine_Drug_Resource_Mappings.xlsx2023-04-10T17:59:30.000Z"cacbc7ed9a2a3a809097e2f93dbab6a5"34018STANDARDdata/guideline/publication/TCA/Desipramine_Drug_Resource_Mappings.xlsx2023-04-10T17:59:31.000Z"acc3c373c84a2fc9f2ea3432a9cabf39"32568STANDARDdata/guideline/publication/TCA/Doxepin_Drug_Resource_Mappings.xlsx2023-04-10T17:59:31.000Z"8713cc5a1ca563806eb5140c8b398b26"37757STANDARDdata/guideline/publication/TCA/Imipramine_Drug_Resource_Mappings.xlsx2023-04-10T17:59:31.000Z"c300f64fd5349202e53c3795fa2f63f6"35435STANDARDdata/guideline/publication/TCA/Nortriptyline_Drug_Resource_Mappings.xlsx2023-04-10T17:59:31.000Z"203d785215d275afe3789967db1743d5"8815STANDARDdata/guideline/publication/TCA/Trimipramine_Drug_Resource_Mappings.xlsx2023-04-10T17:59:31.000Z"af6bcb7d0cf1f8fae45baf72e381fb84"35256STANDARDdata/guideline/publication/abacavir/2021-05-06T17:35:19.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/abacavir/2012/2021-05-06T17:35:19.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/abacavir/2012/22378157-supplement.pdf2023-04-10T17:59:32.000Z"5448fbd35b643e11377c22ba84b7160f"385648STANDARDdata/guideline/publication/abacavir/2012/22378157.pdf2023-04-10T17:59:32.000Z"9f64f2316a15d9c4f5c365e108f9712f"135101STANDARDdata/guideline/publication/abacavir/2014/2021-05-06T17:35:19.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/abacavir/2014/24561393-supplement.pdf2023-04-10T17:59:32.000Z"4ecc754d2f1dce8b7086b2ccd3076e24"834453STANDARDdata/guideline/publication/abacavir/2014/24561393.pdf2023-04-10T17:59:33.000Z"fb69ee0277542cbb435e42ec322b06a8"171957STANDARDdata/guideline/publication/abacavir/Abacavir_Drug_Resource_Mappings.xlsx2023-04-10T17:59:33.000Z"7b326ca32fe375868450278f4d4313e9"36906STANDARDdata/guideline/publication/allopurinol/2021-05-06T17:35:19.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/allopurinol/2013/2021-05-06T17:35:19.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/allopurinol/2013/23232549-supplement.pdf2023-04-10T17:59:33.000Z"8ba98fac4afcd4c6e082bf651b2eda97"134745STANDARDdata/guideline/publication/allopurinol/2013/23232549.pdf2023-04-10T17:59:34.000Z"735a101c4444e6a25960ae6758e4c888"242420STANDARDdata/guideline/publication/allopurinol/2015/2021-05-06T17:35:19.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/allopurinol/2015/26094938-supplement.pdf2023-04-10T17:59:36.000Z"c3016a865743424cdf1110b3524b3b71"1961424STANDARDdata/guideline/publication/allopurinol/2015/26094938.pdf2023-04-10T17:59:36.000Z"78302ce133bc128909779d9222a8c1ed"104084STANDARDdata/guideline/publication/allopurinol/Allopurinol_Drug_Resource_Mappings.xlsx2023-04-10T17:59:36.000Z"d1fe5422c791fa7e85b4dacee1c48d7f"37386STANDARDdata/guideline/publication/aminoglycosides/2021/34032273-supplement.pdf2025-10-27T22:12:15.000Z"6a1014251d3bf29618791b0b7f0d2a03"CRC64NVMEFULL_OBJECT243590STANDARDdata/guideline/publication/aminoglycosides/2021/34032273.pdf2023-04-10T17:59:37.000Z"4818af830e5f0d9751e179aef4118c9d-2"10912011STANDARDdata/guideline/publication/atazanavir/2021-05-06T17:35:19.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/atazanavir/2015/2021-05-06T17:35:19.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/atazanavir/2015/26417955-UGT1A1_allele_frequency.xlsx2023-04-10T17:59:38.000Z"e6976ba34f61d77e3cf2ae5d4eed51d4"58430STANDARDdata/guideline/publication/atazanavir/2015/26417955-supplement.pdf2023-04-10T17:59:38.000Z"99a961fb0d494e6ef603cd3e7eb39f39"1426991STANDARDdata/guideline/publication/atazanavir/2015/26417955.pdf2023-04-10T17:59:38.000Z"e49e3a84c1d29a8b23375e53a2429f6a"229913STANDARDdata/guideline/publication/atazanavir/Atazanavir_Drug_Resource_Mappings.xlsx2023-04-10T17:59:41.000Z"3ae8fdc64a6c28219e0cbc83ce94c89b"37031STANDARDdata/guideline/publication/atomoxetine/2021-05-06T17:35:19.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/atomoxetine/2019/2021-05-06T17:35:19.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/atomoxetine/2019/30801677-supplement.pdf2023-04-10T17:59:41.000Z"44240a2f806ac4eeea185b1c12e26ca5"447535STANDARDdata/guideline/publication/atomoxetine/2019/30801677.pdf2023-04-10T17:59:42.000Z"e0f6c4c92b51acb215905a4e30f20747"312242STANDARDdata/guideline/publication/atomoxetine/Atomoxetine_Drug_Resource_Mappings.xlsx2023-04-10T17:59:44.000Z"99cec11d40cdcb4762c01bce7dcb7586"9355STANDARDdata/guideline/publication/atomoxetine/atomoxetine_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2023-04-10T17:59:44.000Z"ea19a54d41da66753ac8928fecdbca23"16678STANDARDdata/guideline/publication/beta_blockers/2024/38951961-supplement.pdf2025-08-26T23:41:11.000Z"f8f677aedebd1b24b31038ae74fb9e50"CRC64NVMEFULL_OBJECT1602813STANDARDdata/guideline/publication/beta_blockers/2024/38951961.pdf2025-08-26T23:41:11.000Z"9095188ae3f915b2e6dc6995a5b9edab"CRC64NVMEFULL_OBJECT284575STANDARDdata/guideline/publication/carbamazepine/2021-05-06T17:35:19.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/carbamazepine/2013/2021-05-06T17:35:28.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/carbamazepine/2013/23695185-supplement.pdf2023-04-10T17:59:45.000Z"a17ac1a40c3e5dfd12a3dcbcf90bad7d"173891STANDARDdata/guideline/publication/carbamazepine/2013/23695185.pdf2023-04-10T17:59:45.000Z"7b45829d772d1a47fb12726c8ca5f384"195363STANDARDdata/guideline/publication/carbamazepine/2017/2021-05-06T17:35:28.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/carbamazepine/2017/29392710-supplement.pdf2023-04-10T17:59:46.000Z"31be5f0b917b79d6702b92386f02982f"465113STANDARDdata/guideline/publication/carbamazepine/2017/29392710.pdf2023-04-10T17:59:46.000Z"f86bf0fcbc9b21eb8a1192bd63e4731d"173773STANDARDdata/guideline/publication/carbamazepine/2017/CPIC_HLA_CBZ_OXC.pdf2021-05-06T17:35:30.000Z"f86bf0fcbc9b21eb8a1192bd63e4731d"173773STANDARDdata/guideline/publication/carbamazepine/2017/CPIC_HLA_CBZ_OXC_Supplemental_Material.pdf2021-05-06T17:35:30.000Z"31be5f0b917b79d6702b92386f02982f"465113STANDARDdata/guideline/publication/carbamazepine/2017/CPIC_HLA_CBZ_OXC_submitted_version.pdf2021-05-06T17:35:29.000Z"1d9169f7c4d6a8092f9cc0f2c0ff83ae"409983STANDARDdata/guideline/publication/carbamazepine/CBZ_OXC_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2023-04-10T17:59:49.000Z"d7199f5466634a184d8108f01301880a"256714STANDARDdata/guideline/publication/carbamazepine/Carbamazepine_Drug_Resource_Mappings.xlsx2023-04-10T17:59:49.000Z"c427d75bc0151ef8cf002b2c6a3bea93"35556STANDARDdata/guideline/publication/carbamazepine/Oxcarbazepine_Drug_Resource_Mappings.xlsx2023-04-10T17:59:49.000Z"42e01bf931f8ada8a2b39db0387d7e49"31139STANDARDdata/guideline/publication/clopidogrel/2021-05-06T17:35:19.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/clopidogrel/2011/2021-05-06T17:35:32.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/clopidogrel/2011/21716271-supplement.pdf2023-04-10T17:59:49.000Z"403466fcdebf4c57ec7e641aa141d811"1412073STANDARDdata/guideline/publication/clopidogrel/2011/21716271.pdf2023-04-10T17:59:49.000Z"a64d373e332f3f8b9b892dfc6b82c94a"151974STANDARDdata/guideline/publication/clopidogrel/2013/2021-05-06T17:35:32.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/clopidogrel/2013/23698643-supplement.pdf2023-04-10T17:59:50.000Z"63fdbdb8e219256d98887239556cf6fc"489753STANDARDdata/guideline/publication/clopidogrel/2013/23698643.pdf2023-04-10T17:59:51.000Z"a6d5d49e1d9554978aa26362a66e045c"250786STANDARDdata/guideline/publication/clopidogrel/2022/35034351-supplement.pdf2023-04-10T17:59:52.000Z"77cd7dac63ec8200fcd69981ba380a4c"1208424STANDARDdata/guideline/publication/clopidogrel/2022/35034351.pdf2022-03-01T19:15:18.000Z"c0f1a260d565e5628d7b8f862a5ac595"176977STANDARDdata/guideline/publication/clopidogrel/Clopidogrel_Drug_Resource_Mappings.xlsx2023-04-10T17:59:52.000Z"f08f6cd97106b15285994abd42d78e61"37593STANDARDdata/guideline/publication/clopidogrel/Clopidogrel_Pre_and_Post_Test_Alerts.xlsx2023-04-10T17:59:53.000Z"fd21605c77d2dcafa68d76c5c771c98c"142741STANDARDdata/guideline/publication/codeine/2021-05-06T17:35:35.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/codeine/2012/2021-05-06T17:35:35.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/codeine/2012/22205192-CYP2D6-allele_frequency_table.xlsx2023-04-10T17:59:54.000Z"13ce48afb1c9fd7492c51d144453d900"145617STANDARDdata/guideline/publication/codeine/2012/22205192-CYP2D6-allele_table_and_legend.pdf2023-04-10T17:59:56.000Z"bc6f4e5ce1e6c60390fe98ada1d82d67"1022192STANDARDdata/guideline/publication/codeine/2012/22205192-supplement.pdf2023-04-10T17:59:56.000Z"6271f9095075bc7719d9c11cd51c9b0a"572376STANDARDdata/guideline/publication/codeine/2012/22205192.pdf2023-04-10T17:59:57.000Z"4ee7e3b37379ec7fcac9a8bb42783c32"165132STANDARDdata/guideline/publication/codeine/2014/2021-05-06T17:35:35.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/codeine/2014/24458010-CYP2D6_allele_frequency_table_(R2).xlsx2023-04-10T17:59:59.000Z"1dffdfbb2bda910eefbcca7edd6687c0"305976STANDARDdata/guideline/publication/codeine/2014/24458010-CYP2D6_allele_table_and_legend_(R2).pdf2023-04-10T18:00:00.000Z"d41697335b345d43e7bcdfd3d6e284be"1022028STANDARDdata/guideline/publication/codeine/2014/24458010-supplement.pdf2023-04-10T18:00:01.000Z"4730179edb9e0d65ecf91ac01c9350be"276636STANDARDdata/guideline/publication/codeine/2014/24458010.pdf2023-04-10T18:00:03.000Z"7d93da22912a9cdfe76c9e3c7f4f6a4f"315197STANDARDdata/guideline/publication/codeine/Codeine_Drug_Resource_Mappings.xlsx2023-04-10T18:00:03.000Z"0ce91434ac8c7a6f892bceb7b905cfbe"36941STANDARDdata/guideline/publication/efavirenz/2021-05-06T17:35:34.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/efavirenz/2019/2021-05-06T17:35:35.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/efavirenz/2019/31006110-supplement.pdf2023-04-10T18:00:04.000Z"f4654b4106cbc42fe01b8147beed82a3"514470STANDARDdata/guideline/publication/efavirenz/2019/31006110.pdf2023-04-10T18:00:05.000Z"505ce90c99a041604f021cb92e583f31"342349STANDARDdata/guideline/publication/efavirenz/Efavirenz_Drug_Resource_Mappings.xlsx2023-04-10T18:00:05.000Z"5495d883529bb439434c677c75809514"9264STANDARDdata/guideline/publication/efavirenz/Efavirenz_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2023-04-10T18:00:05.000Z"8f208d9f800c12732f28df43d021fa89"149227STANDARDdata/guideline/publication/fluoropyrimidines/2021-05-06T17:35:35.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/fluoropyrimidines/2013/2021-05-06T17:35:42.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/fluoropyrimidines/2013/23988873-supplement.pdf2023-04-10T18:00:06.000Z"c0d2d992e7fecf1e16232f9d9f21deb6"340213STANDARDdata/guideline/publication/fluoropyrimidines/2013/23988873.pdf2023-04-10T18:00:06.000Z"cb794ca42e07c41db8358d25fb420e84"183365STANDARDdata/guideline/publication/fluoropyrimidines/2013/Capecitabine_Drug_Resource_Mappings.xlsx2021-05-06T17:35:42.000Z"d249c0ff1440e7cd916ce2d71b4a8628"37886STANDARDdata/guideline/publication/fluoropyrimidines/2013/Fluorouracil_Drug_Resource_Mappings.xlsx2021-05-06T17:35:43.000Z"41fff2ccb1d5f8717ee9fedc14ff080c"37416STANDARDdata/guideline/publication/fluoropyrimidines/2013/Tegafur_Drug_Response_Mappings.xlsx2021-05-06T17:35:43.000Z"e650bbf12d29296baff81173fd646d7b"31557STANDARDdata/guideline/publication/fluoropyrimidines/2017/2021-05-06T17:35:42.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/fluoropyrimidines/2017/29152729-supplement.pdf2023-04-10T18:00:07.000Z"eb7276631f5f8f3ad77dd4f0d4169d2e"944377STANDARDdata/guideline/publication/fluoropyrimidines/2017/29152729.pdf2023-04-10T18:00:09.000Z"dddc21a66b6a4f52ec64cced2e9f54bb"154629STANDARDdata/guideline/publication/fluoropyrimidines/2017/DPYD_preprint-supplement.pdf2021-05-06T17:35:44.000Z"f316498b7692b81a2bdd2f6faf68d04f"944378STANDARDdata/guideline/publication/fluoropyrimidines/2017/DPYD_preprint.pdf2021-05-06T17:35:46.000Z"61705312e323fecc290a473a5809be93"180709STANDARDdata/guideline/publication/fluoropyrimidines/Capecitabine_Drug_Resource_Mappings.xlsx2023-04-10T18:00:09.000Z"d249c0ff1440e7cd916ce2d71b4a8628"37886STANDARDdata/guideline/publication/fluoropyrimidines/Fluoropyrimidines_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2023-04-10T18:00:10.000Z"0603707ef2f69943f32c1fd3749b3936"37251STANDARDdata/guideline/publication/fluoropyrimidines/Fluorouracil_Drug_Resource_Mappings.xlsx2023-04-10T18:00:10.000Z"41fff2ccb1d5f8717ee9fedc14ff080c"37416STANDARDdata/guideline/publication/fluoropyrimidines/Fluorouracil_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2023-04-10T18:00:10.000Z"9edf78b80082d0f79699cd56b6940eba"37442STANDARDdata/guideline/publication/fluoropyrimidines/Tegafur_Drug_Resource_Mappings.xlsx2023-04-10T18:00:10.000Z"e650bbf12d29296baff81173fd646d7b"31557STANDARDdata/guideline/publication/hydralazine/2025/40974042-supplement.pdf2025-10-27T22:12:16.000Z"0f7cff2bf0eb908760a8920710f8e7cd"CRC64NVMEFULL_OBJECT460083STANDARDdata/guideline/publication/hydralazine/2025/40974042.pdf2025-10-27T22:12:16.000Z"a0478aa459d2140d3fa521a44a0c18de"CRC64NVMEFULL_OBJECT278992STANDARDdata/guideline/publication/hydralazine/2025/NAT2_hydralazine_publication.pdf2025-09-24T17:08:38.000Z"0e916e1ba1f80d31de1de4154c474a34"CRC64NVMEFULL_OBJECT375502STANDARDdata/guideline/publication/hydralazine/2025/NAT2_hydralazine_supplement.pdf2025-09-24T17:08:38.000Z"0f7cff2bf0eb908760a8920710f8e7cd"CRC64NVMEFULL_OBJECT460083STANDARDdata/guideline/publication/ivacaftor/2021-05-06T17:35:48.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/ivacaftor/2014/2021-05-06T17:35:48.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/ivacaftor/2014/24598717-supplement.pdf2025-08-26T23:41:11.000Z"e152d7bbc4bce36c47f465babfb0d569"CRC64NVMEFULL_OBJECT732276STANDARDdata/guideline/publication/ivacaftor/2014/24598717.pdf2023-04-10T18:00:10.000Z"9d7dafda429643eb294de2fe9bd901f6"144582STANDARDdata/guideline/publication/ivacaftor/2014/Ivacaftor_Drug_Resource_Mappings.xlsx2023-04-10T18:00:11.000Z"29c9cb48c6cf8a8332cf160604d82b18"37076STANDARDdata/guideline/publication/ivacaftor/Ivacaftor_Drug_Resource_Mappings.xlsx2023-04-10T18:00:11.000Z"29c9cb48c6cf8a8332cf160604d82b18"37076STANDARDdata/guideline/publication/methadone/2024/38863207-supplement.pdf2025-08-26T23:41:11.000Z"4a3c873a4d95904333bafa5076f2acf9"CRC64NVMEFULL_OBJECT421445STANDARDdata/guideline/publication/methadone/2024/38863207.pdf2025-08-26T23:41:11.000Z"3ee17fcd06957179e7171b7b2346c8db"CRC64NVMEFULL_OBJECT279288STANDARDdata/guideline/publication/ondansetron/2021-05-06T17:35:48.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/ondansetron/2016/2021-05-06T17:35:58.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/ondansetron/2016/28002639-supplement.pdf2023-04-10T18:00:11.000Z"e610d4e3125439894fe5bafebd09eb6b"423789STANDARDdata/guideline/publication/ondansetron/2016/28002639.pdf2023-04-10T18:00:11.000Z"43e685d8b32fb83221f757343489201d"147448STANDARDdata/guideline/publication/ondansetron/2016/Ondansetron_Drug_Resource_Mappings.xlsx2023-04-10T18:00:11.000Z"b68bc1f411ba528389005878530ede49"9055STANDARDdata/guideline/publication/ondansetron/2016/Ondansetron_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2023-04-10T18:00:11.000Z"e5d09af6bf793916e9eed4e626960ca4"62509STANDARDdata/guideline/publication/ondansetron/2016/Tropisetron_Drug_Resource_Mappings.xlsx2023-04-10T18:00:12.000Z"9baa82aecc2a5c18f8de2d9755b7a8b1"9025STANDARDdata/guideline/publication/ondansetron/Ondansetron_Drug_Resource_Mappings.xlsx2023-04-10T18:00:12.000Z"62527a359739ce37578697ce7ff3cde3"9055STANDARDdata/guideline/publication/ondansetron/Tropisetron_Drug_Resource_Mappings.xlsx2023-04-10T18:00:12.000Z"afb0e53444c0688a08e9e6bd591eff04"9025STANDARDdata/guideline/publication/opioids/2021-05-06T17:36:00.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/opioids/2020/2021-05-06T17:36:00.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/opioids/2020/33387367-supplement.pdf2023-04-10T18:00:12.000Z"2b1b18f972261cd7c53b8d0e9391d7f6"2020408STANDARDdata/guideline/publication/opioids/2020/33387367.pdf2023-04-10T18:00:12.000Z"f68f0b6bbabca59db02063c583c28546"187889STANDARDdata/guideline/publication/opioids/2020/CPIC_opioids_PREPRINT-supplement.pdf2021-05-06T17:36:01.000Z"2b1b18f972261cd7c53b8d0e9391d7f6"2020408STANDARDdata/guideline/publication/opioids/2020/CPIC_opioids_PREPRINT.pdf2021-05-06T17:36:01.000Z"5656b00a2a39536f3081a377398e5752"487551STANDARDdata/guideline/publication/opioids/codeine-Drug_Resource_Mappings.xlsx2023-04-10T18:00:13.000Z"1e4e06f88734af6cbd53b7027080e709"3909STANDARDdata/guideline/publication/opioids/codeine_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2023-04-10T18:00:13.000Z"58731fea6aa767414329cd893b11b795"55272STANDARDdata/guideline/publication/opioids/hydrocodone-Drug_Resource_Mappings.xlsx2023-04-10T18:00:14.000Z"f56b5161cbcdd75510a9e375e6305333"3802STANDARDdata/guideline/publication/opioids/hydrocodone_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2023-04-10T18:00:14.000Z"0b3c74a76ae10681165bdbf02329fde6"55453STANDARDdata/guideline/publication/opioids/tramadol-Drug_Resource_Mappings.xlsx2023-04-10T18:00:15.000Z"1ba7d7b14af37893260dbd7cd82eb185"8855STANDARDdata/guideline/publication/opioids/tramadol_Pre_and_Post_Test_Alerts.xlsx2023-04-10T18:00:15.000Z"f91aa2f3e6ffe7844c19ba091d5fe305"55543STANDARDdata/guideline/publication/pegintron/2021-05-06T17:36:00.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/pegintron/2013/2021-05-06T17:36:03.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/pegintron/2013/24096968-supplement.pdf2023-04-10T18:00:15.000Z"57894a208fca996ccb473bb67b7afcb4"483425STANDARDdata/guideline/publication/pegintron/2013/24096968.pdf2023-04-10T18:00:15.000Z"352373e21a13e8ea0bd30d5e54c22300"228567STANDARDdata/guideline/publication/pegintron/Peginterferon_alfa-2a_Drug_Resource_Mappings.xlsx2023-04-10T18:00:15.000Z"bbef8639fce17dbed10ecb0abb4ab0f8"34192STANDARDdata/guideline/publication/pegintron/Peginterferon_alfa-2b_Drug_Resource_Mappings.xlsx2023-04-10T18:00:16.000Z"9bf051a2dc80dd9a4466d8dae982a78e"34201STANDARDdata/guideline/publication/pegintron/Ribavirin_Drug_Resource_Mappings.xlsx2023-04-10T18:00:16.000Z"7e55cbb5e12fe17762f465ce57c17064"31952STANDARDdata/guideline/publication/phenytoin/2021-05-06T17:36:00.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/phenytoin/2014/2021-05-06T17:36:05.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/phenytoin/2014/25099164-Phenytoin_translation_table_final.xlsx2023-04-10T18:00:17.000Z"20ced77dd6291cee4ca52c555c24760b"54568STANDARDdata/guideline/publication/phenytoin/2014/25099164-supplement.doc2023-04-10T18:00:17.000Z"6395d7a1739a6d23acb69089c84414f0"1318400STANDARDdata/guideline/publication/phenytoin/2014/25099164-supplement.pdf2023-04-10T18:00:17.000Z"7e9ca99c5fee28e14e87cd9060b7037f"1198250STANDARDdata/guideline/publication/phenytoin/2014/25099164.pdf2023-04-10T18:00:17.000Z"498b51154b75d7ae7750b336b668a27c"326822STANDARDdata/guideline/publication/phenytoin/2020/2021-05-06T17:36:05.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/phenytoin/2020/32779747-supplement.pdf2023-04-10T18:00:17.000Z"3a5b9de07c0d8332b57279abaaf44a40"561125STANDARDdata/guideline/publication/phenytoin/2020/32779747.pdf2023-04-10T18:00:18.000Z"85064982355415635de896dce58188b5"351658STANDARDdata/guideline/publication/phenytoin/Fosphenytoin-Drug_Resource_Mappings.xlsx2023-04-10T18:00:19.000Z"453a80b60eb4a8fe2f95d11e50de1699"8857STANDARDdata/guideline/publication/phenytoin/Fosphenytoin_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2023-04-10T18:00:19.000Z"bc67b8e374c83f0cf88d1381feaac1bc"370355STANDARDdata/guideline/publication/phenytoin/Phenytoin_Drug_Resource_Mappings.xlsx2023-04-10T18:00:19.000Z"aa25d61b11b015def7e37d4bd8ba5aeb"8849STANDARDdata/guideline/publication/phenytoin/Phenytoin_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2023-04-10T18:00:20.000Z"253c1eb2086b9f00a12e257028f9bf81"142889STANDARDdata/guideline/publication/rasburicase/2021-05-06T17:36:18.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/rasburicase/2014/2021-05-06T17:36:19.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/rasburicase/2014/24787449-supplement.pdf2023-04-10T18:00:22.000Z"57f18680c1a0790e28547d73351905a5"946511STANDARDdata/guideline/publication/rasburicase/2014/24787449.pdf2023-04-10T18:00:22.000Z"8dd393cbab20426e36d2e71e3ec5b7f1"286502STANDARDdata/guideline/publication/rasburicase/Rasburicase_Drug_Resource_Mappings.xlsx2023-04-10T18:00:23.000Z"cd734bfec0d2c795775b76754af1fe4a"32424STANDARDdata/guideline/publication/serotonin_reuptake_inhibitor_antidepressants/2023/37032427-supplement.pdf2023-06-22T20:36:13.000Z"2dd62f90e3b4498f0aa28b23e551c5e0"1261176STANDARDdata/guideline/publication/serotonin_reuptake_inhibitor_antidepressants/2023/37032427.pdf2024-07-24T04:58:59.000Z"f986a82d3276805f9277deb12398a3d2"355964STANDARDdata/guideline/publication/simvastatin/2021-05-06T17:36:19.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/simvastatin/2012/2021-05-06T17:36:19.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/simvastatin/2012/22617227-supplement.pdf2023-04-10T18:00:25.000Z"922b1d9c6eaad5064be98140b7647547"705187STANDARDdata/guideline/publication/simvastatin/2012/22617227.pdf2023-04-10T18:00:28.000Z"e46aea3c5511a6725374dfde26a805e6"273663STANDARDdata/guideline/publication/simvastatin/2014/2021-05-06T17:36:19.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/simvastatin/2014/24918167-supplement.pdf2023-04-10T18:00:31.000Z"eb348abbb493d69d916a85eab85bf4e6"1137870STANDARDdata/guideline/publication/simvastatin/2014/24918167.pdf2023-04-10T18:00:34.000Z"2472e1cbdda9f8e8c856b0631bf4b4b0"233604STANDARDdata/guideline/publication/simvastatin/2014/24918167.xlsx2023-04-10T18:00:34.000Z"47037e22e2e05d2901b3db03ce5ecdf0"35143STANDARDdata/guideline/publication/simvastatin/Simvastatin_Drug_Resource_Mappings.xlsx2023-04-10T18:00:35.000Z"6c790354b7a4386e33e946181b26d408"32430STANDARDdata/guideline/publication/statins/2022/publication.pdf2025-08-26T23:41:11.000Z"4385de64c520950fec2973250e08c98e"CRC64NVMEFULL_OBJECT813287STANDARDdata/guideline/publication/statins/2022/supplement.pdf2023-04-10T18:00:35.000Z"47f4222636d89b030ebafa3e7575c2d9"748597STANDARDdata/guideline/publication/tacrolimus/2021-05-06T17:36:19.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/tacrolimus/2015/2021-05-06T17:36:28.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/tacrolimus/2015/25801146-CYP3A5_allele_frequency_table.xlsx2023-04-10T18:00:36.000Z"37f81a2da1aa6bb8843334242f81ee70"57588STANDARDdata/guideline/publication/tacrolimus/2015/25801146-CYP3A5_translation_table.xlsx2023-04-10T18:00:36.000Z"265c47781dc9f182d22987259c01949d"44143STANDARDdata/guideline/publication/tacrolimus/2015/25801146-supplement.pdf2023-04-10T18:00:37.000Z"a8c8308171ea71830d54f99b95db67ab"669981STANDARDdata/guideline/publication/tacrolimus/2015/25801146.pdf2023-04-10T18:00:37.000Z"5a580976ffa9ecda21085e10d72cfb67"152084STANDARDdata/guideline/publication/tacrolimus/Tacrolimus_Drug_Resource_Mappings.xlsx2023-04-10T18:00:37.000Z"f241f33437dfca37fd4c28ac172df5d3"32304STANDARDdata/guideline/publication/tamoxifen/2021-05-06T17:36:28.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/tamoxifen/2017/2021-05-06T17:36:29.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/tamoxifen/2017/29385237-supplement.pdf2023-04-10T18:00:37.000Z"f90cc5d135332f28a123fefce20d9af2"415827STANDARDdata/guideline/publication/tamoxifen/2017/29385237.pdf2023-04-10T18:00:37.000Z"000a266c1f7795334f0c05408cdaad05"328176STANDARDdata/guideline/publication/tamoxifen/2017/tamoxifen_reprint.pdf2023-04-10T18:00:38.000Z"000a266c1f7795334f0c05408cdaad05"328176STANDARDdata/guideline/publication/tamoxifen/2017/tamoxifen_reprint_supplement.pdf2023-04-10T18:00:40.000Z"f90cc5d135332f28a123fefce20d9af2"415827STANDARDdata/guideline/publication/tamoxifen/Tamoxifen_Drug_Resource_Mappings.xlsx2023-04-10T18:00:40.000Z"af1e41f7c64dbed9cda72ad2ea49f98f"9101STANDARDdata/guideline/publication/tamoxifen/Tamoxifen_Pre_and_Post_Test_Alerts_and_Flow.xlsx2023-04-10T18:00:41.000Z"dd555985482dd2de91ce88f2e2b306ab"17201STANDARDdata/guideline/publication/thiopurines/2021-05-06T17:36:38.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/thiopurines/2011/2021-05-06T17:36:38.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/thiopurines/2011/21270794-supplement.pdf2023-04-10T18:00:41.000Z"1f8a4663ad013e2115750b28f408b450"572838STANDARDdata/guideline/publication/thiopurines/2011/21270794.pdf2023-04-10T18:00:42.000Z"ca315fd1a23a584fcde03a8a7e0f1b05"158775STANDARDdata/guideline/publication/thiopurines/2013/2021-05-06T17:36:38.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/thiopurines/2013/23422873-supplement.pdf2023-04-10T18:00:42.000Z"f44b685c0f043eff3dce0ac8b1cd6595"788271STANDARDdata/guideline/publication/thiopurines/2013/23422873.pdf2023-04-10T18:00:43.000Z"89e3a72ff1c805bd9bd6513fb1a2e313"144150STANDARDdata/guideline/publication/thiopurines/2018/2021-05-06T17:36:38.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/thiopurines/2018/30447069-supplement.pdf2023-04-10T18:00:45.000Z"ca1c7ed0989ac906781f55b9fba1125a"515874STANDARDdata/guideline/publication/thiopurines/2018/30447069.pdf2023-04-10T18:00:45.000Z"45ba310844ca415066d85ef8196341b9"367119STANDARDdata/guideline/publication/thiopurines/2018/CPIC_TPMT_NUDT15_Thiopurine_Submitted.pdf2023-04-10T18:00:45.000Z"af09876cc5b45a980b54b1f3b971c3b8"419068STANDARDdata/guideline/publication/thiopurines/2018/CPIC_TPMT_NUDT15_Thiopurine_Supplemental_Material.pdf2023-04-10T18:00:47.000Z"cc7f02f920cd4ac89de3d3cfd873c865"515904STANDARDdata/guideline/publication/thiopurines/2018/CPIC_TPMT_NUDT15_Thiopurine_formatted.pdf2023-04-10T18:00:47.000Z"ad26881e74aa543fbcbfd6316930943d"366938STANDARDdata/guideline/publication/thiopurines/2018/CPIC_TPMT_NUDT15_Thiourine_Submitted.pdf2023-04-10T18:00:48.000Z"d658b77e22a19eebf4f422acdaf73db9"1830467STANDARDdata/guideline/publication/thiopurines/2026/41618934-supplement.pdf2026-02-03T23:28:47.000Z"8488a52949104d0b56c4d8aac407073f"CRC64NVMEFULL_OBJECT1086510STANDARDdata/guideline/publication/thiopurines/2026/41618934.pdf2026-02-03T23:28:47.000Z"ddb800c2f243d62cb4a371c00bb85caa"CRC64NVMEFULL_OBJECT427592STANDARDdata/guideline/publication/thiopurines/Azathioprine_Drug_Resource_Mappings.xlsx2023-04-10T18:00:48.000Z"631d9f83908300faea900f1c9afa6f2a"37723STANDARDdata/guideline/publication/thiopurines/Mercaptopurine_Drug_Resource_Mappings.xlsx2023-04-10T18:00:49.000Z"94ccfe310fc98f134f43093875f5a159"33275STANDARDdata/guideline/publication/thiopurines/Thioguanine_Drug_Resource_Mappings.xlsx2023-04-10T18:00:50.000Z"b361075fb7d0fbd01a32f0f888e33f0d"32304STANDARDdata/guideline/publication/thiopurines/Thiopurines_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2023-04-10T18:00:50.000Z"f383b2e98aa785e4e94edf1a53c8f44b"125306STANDARDdata/guideline/publication/thiopurines/azathioprine_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2023-04-10T18:00:50.000Z"bb83ea2b4b04516d1cd6d2783c11aa0d"124109STANDARDdata/guideline/publication/thiopurines/azathioprine_recommendation.xlsx2023-04-10T18:00:51.000Z"e55ded4b6c233427adc310b0461747dc"12546STANDARDdata/guideline/publication/thiopurines/mercaptopurine_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2023-04-10T18:00:51.000Z"06fcc25fbf1e033892ba605309a556f8"125199STANDARDdata/guideline/publication/thiopurines/mercaptopurine_recommendation.xlsx2023-04-10T18:00:51.000Z"ac0e3f3d45c1e1d702cbba4a2b770cb4"13264STANDARDdata/guideline/publication/thiopurines/thioguanine_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2023-04-10T18:00:51.000Z"1967a806507fe1df9b94a1ef9e8566dc"123856STANDARDdata/guideline/publication/thiopurines/thioguanine_recommendation.xlsx2023-04-10T18:00:52.000Z"99158cf42a034747eb423c3c0adfbef4"13093STANDARDdata/guideline/publication/volatile_anesthetic_succinylcholine/2021-05-06T17:36:38.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/volatile_anesthetic_succinylcholine/2018/2021-05-06T17:36:38.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/volatile_anesthetic_succinylcholine/2018/30499100-supplement.pdf2023-04-10T18:00:52.000Z"478b1962a060129ff695fb737c72a909"423262STANDARDdata/guideline/publication/volatile_anesthetic_succinylcholine/2018/30499100.pdf2023-04-10T18:00:52.000Z"dcd9dc1eae6777767f32c0afe2d8089a"172754STANDARDdata/guideline/publication/volatile_anesthetic_succinylcholine/Desflurane_Drug_Resource_Mappings.xlsx2023-04-10T18:00:53.000Z"e37c3bbf9ac87f1f62fce75e01a2797f"9210STANDARDdata/guideline/publication/volatile_anesthetic_succinylcholine/Enflurane_Drug_Resource_Mappings.xlsx2023-04-10T18:00:53.000Z"565bfab0c1f50e9157f269df8bee39cf"9181STANDARDdata/guideline/publication/volatile_anesthetic_succinylcholine/Halothane_Drug_Resource_Mappings.xlsx2023-04-10T18:00:53.000Z"f0717b07a3744bd64a35b3ad008ba2e5"9171STANDARDdata/guideline/publication/volatile_anesthetic_succinylcholine/Isoflurane_Drug_Resource_Mappings.xlsx2023-04-10T18:00:53.000Z"113be7de90768abd9500ccb71bd40252"9177STANDARDdata/guideline/publication/volatile_anesthetic_succinylcholine/Methoxyflurane_Drug_Resource_Mappings.xlsx2023-04-10T18:00:53.000Z"63c66498fc5c7065c2eacd5efb196aab"9191STANDARDdata/guideline/publication/volatile_anesthetic_succinylcholine/Sevoflurane_Drug_Resource_Mappings.xlsx2023-04-10T18:00:53.000Z"11dbd2f3ce37af1c64bdc5f5b701522b"9180STANDARDdata/guideline/publication/volatile_anesthetic_succinylcholine/Succinylcholine_Drug_Resource_Mappings.xlsx2023-04-10T18:00:53.000Z"fd0f1bf968aec3080760c2a460884ed1"9186STANDARDdata/guideline/publication/volatile_anesthetic_succinylcholine/volatile_anesthetic_agents_succinylcholine_pre_and_post_test_alerts_and_flow_chart.xlsx2023-04-10T18:00:54.000Z"e8a2b81edb8b086c84c3810e13cc6d04"16241STANDARDdata/guideline/publication/voriconazole/2021-05-06T17:36:38.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/voriconazole/2016/2021-05-06T17:36:47.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/voriconazole/2016/27981572-supplement.pdf2023-04-10T18:00:54.000Z"43d23bf409894533716466dc786c545e"708011STANDARDdata/guideline/publication/voriconazole/2016/27981572.pdf2023-04-10T18:00:54.000Z"d5e7ab95112885f1063f048c61682040"151170STANDARDdata/guideline/publication/voriconazole/2016/Voriconazole_2016.pdf2023-04-10T18:00:54.000Z"18387c5644bd879d0e4cbcfcf712528c"296617STANDARDdata/guideline/publication/voriconazole/2016/Voriconazole_Drug_Resource_Mappings.xlsx2023-04-10T18:00:54.000Z"4eeda2e3b7e34e9f27aea9131c8f398a"35367STANDARDdata/guideline/publication/voriconazole/2016/Voriconazole_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx2023-04-10T18:00:54.000Z"c4d08110f1667ee4c367d2f7d08254f1"55825STANDARDdata/guideline/publication/voriconazole/2016/Voriconazole_Supplement_2016.pdf2023-04-10T18:00:55.000Z"5fb11dbf2f80210dbf7cefcc19431a3f"708020STANDARDdata/guideline/publication/voriconazole/Voriconazole_Drug_Resource_Mappings.xlsx2023-04-10T18:00:55.000Z"c32752d12df5897bfc9e782d8b45a756"32757STANDARDdata/guideline/publication/warfarin/2021-05-06T17:36:38.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/warfarin/2011/2021-05-06T17:36:47.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/warfarin/2011/21900891-supplement.pdf2023-04-10T18:00:56.000Z"237e892b1f5b0c5e308a3fda0ab735b2"340498STANDARDdata/guideline/publication/warfarin/2011/21900891.pdf2023-04-10T18:00:56.000Z"3d27a54274390cf55b82ab7a651a68ca"177306STANDARDdata/guideline/publication/warfarin/2011/IWPC_dose_calculator.xls2023-04-10T18:00:56.000Z"65096044c60017b2b538738ba733475f"56320STANDARDdata/guideline/publication/warfarin/2017/2021-05-06T17:36:51.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/guideline/publication/warfarin/2017/28198005-supplement.pdf2023-04-10T18:00:56.000Z"0af36c9544b52cde6ee51a72aa571842"498971STANDARDdata/guideline/publication/warfarin/2017/28198005.pdf2023-04-10T18:00:57.000Z"d59c23ed0a278843a94f9eb7494389ff"410744STANDARDdata/guideline/publication/warfarin/2017/CYP2C9_frequency_table.xlsx2023-04-10T18:00:58.000Z"20c17b7ac89a1c8017c508b2461e97b2"74252STANDARDdata/guideline/publication/warfarin/2017/CYP4F2_frequency_table.xlsx2023-04-10T18:00:59.000Z"0a5aa17107b6104336d66a14f05a0f0d"26420STANDARDdata/guideline/publication/warfarin/2017/VKORC1_frequency_table.xlsx2023-04-10T18:00:59.000Z"87db8273280ae9b3603b587d76f13471"30272STANDARDdata/guideline/publication/warfarin/2017/Warfarin_Drug_Resource_Mappings.xlsx2021-05-06T17:36:53.000Z"0d43050f52d56440c7e9221f2333a183"9018STANDARDdata/guideline/publication/warfarin/2017/warfarin-supplement.pdf2021-05-06T17:36:54.000Z"2d78140ee208f82c6d151f99a0793e92"499107STANDARDdata/guideline/publication/warfarin/2017/warfarin.pdf2021-05-06T17:36:51.000Z"3feed6860e1db8346eaba4ab35e2f256"1107908STANDARDdata/guideline/publication/warfarin/Warfarin_Drug_Resource_Mappings.xlsx2023-04-10T18:01:00.000Z"f8e8779bee78faad860e94c7748daa71"31955STANDARDdata/guideline/staging/1643382835/ABCG2_CDS.xlsx2022-01-28T23:13:58.000Z"d9469a7c22cb2a9d0c86d4222563dc63"4297STANDARDdata/guideline/staging/1643382835/ABCG2_allele_definition_table.xlsx2022-01-28T23:13:57.000Z"395c483318497c33db7d21d4d0147efa"4445STANDARDdata/guideline/staging/1643382835/ABCG2_allele_functionality_reference.xlsx2022-01-28T23:13:57.000Z"d5aeb53c96ba9eb5ee0379edb75ebc6c"4476STANDARDdata/guideline/staging/1643382835/ABCG2_frequency_table.xlsx2022-01-28T23:13:57.000Z"ba3d7fc5f0c7741411270cf5c93754f5"4479STANDARDdata/guideline/staging/1643382835/ABCG2_phenotypes.xlsx2022-01-28T23:13:58.000Z"1f915bf5a30e4e17e614a7395da513d4"4358STANDARDdata/guideline/staging/1643382835/atorvastatin recommendation.xlsx2022-01-28T23:14:03.000Z"2d4144706e9f5f95535c17c21d760eb1"4338STANDARDdata/guideline/staging/1643382835/atorvastatin_Pre_and_Post_Test_Alerts.xlsx2022-01-28T23:14:04.000Z"7fbf8af1c94fd3457280620d754bdcfd"4458STANDARDdata/guideline/staging/1643382835/fluvastatin recommendation.xlsx2022-01-28T23:14:04.000Z"ba759f13da35cb61218aaa9c1d5c9a1c"4412STANDARDdata/guideline/staging/1643382835/fluvastatin_Pre_and_Post_Test_Alerts.xlsx2022-01-28T23:14:04.000Z"d8de4392c816d958a430418d1c989134"4943STANDARDdata/guideline/staging/1643382835/lovastatin recommendation.xlsx2022-01-28T23:14:04.000Z"2719cc3408fd2f241a0c2a27b98f0586"4338STANDARDdata/guideline/staging/1643382835/lovastatin-Drug_Resource_Mappings.xlsx2022-01-28T23:14:00.000Z"b72bf26021736a3bb80ea6820bb9fd24"3897STANDARDdata/guideline/staging/1643382835/lovastatin_Pre_and_Post_Test_Alerts.xlsx2022-01-28T23:14:04.000Z"74937cbcaa9cb41d830ea8bccd34a731"4456STANDARDdata/guideline/staging/1643382835/pitavastatin recommendation.xlsx2022-01-28T23:14:03.000Z"05ba0347fb0d7828662d4d0a9d61ceda"4337STANDARDdata/guideline/staging/1643382835/pitavastatin-Drug_Resource_Mappings.xlsx2022-01-28T23:14:03.000Z"698a33ae9527b0ee03d655e00497a6fd"3900STANDARDdata/guideline/staging/1643382835/pitavastatin_Pre_and_Post_Test_Alerts.xlsx2022-01-28T23:14:03.000Z"2fe5969c48e29a3a9544a06332dedf41"4458STANDARDdata/guideline/staging/1643382835/pravastatin recommendation.xlsx2022-01-28T23:14:03.000Z"598f25e01be397d415369963b624e146"4337STANDARDdata/guideline/staging/1643382835/pravastatin_Pre_and_Post_Test_Alerts.xlsx2022-01-28T23:14:03.000Z"04896411cd895389d8268ad881d65834"4457STANDARDdata/guideline/staging/1643382835/rosuvastatin recommendation.xlsx2022-01-28T23:14:03.000Z"ceb57d9a99b0901730dd1619316a7e83"4386STANDARDdata/guideline/staging/1643382835/rosuvastatin_Pre_and_Post_Test_Alerts.xlsx2022-01-28T23:14:03.000Z"2eff550184a9844ea1bf4ea8dc08be65"4345STANDARDdata/guideline/staging/1643967181/ABCG2_CDS.xlsx2022-02-04T17:33:04.000Z"1a92f7d81ab53d6a5ae47dbafe958151"4298STANDARDdata/guideline/staging/1643967181/ABCG2_allele_definition_table.xlsx2022-02-04T17:33:03.000Z"a450df6d1b1d1f3a2ebf464bfb7b7b9a"4445STANDARDdata/guideline/staging/1643967181/ABCG2_allele_functionality_reference.xlsx2022-02-04T17:33:03.000Z"20ab1a5321da1df6ed233038f31c38b4"4476STANDARDdata/guideline/staging/1643967181/ABCG2_frequency_table.xlsx2022-02-04T17:33:04.000Z"4635f4ea368ab5c1a841483d183d9bb5"4479STANDARDdata/guideline/staging/1643967181/ABCG2_phenotypes.xlsx2022-02-04T17:33:04.000Z"0e36a38faf4a5524666f2e618aca5f99"4359STANDARDdata/guideline/staging/1643967181/atorvastatin recommendation.xlsx2022-02-04T17:33:10.000Z"6ec3122c7fd2589485aa6e56836594ce"6937STANDARDdata/guideline/staging/1643967181/atorvastatin_Pre_and_Post_Test_Alerts.xlsx2022-02-04T17:33:10.000Z"565040204b1b3d3960069893c1dcbaf5"4506STANDARDdata/guideline/staging/1643967181/fluvastatin recommendation.xlsx2022-02-04T17:33:10.000Z"6c777914562c3cfdab29af8a5f6dcc40"8315STANDARDdata/guideline/staging/1643967181/fluvastatin_Pre_and_Post_Test_Alerts.xlsx2022-02-04T17:33:10.000Z"0c73b54c3c5448e991880f01310ed593"5180STANDARDdata/guideline/staging/1643967181/lovastatin recommendation.xlsx2022-02-04T17:33:10.000Z"10d89473cda60e3764f2d865d93b1c66"6938STANDARDdata/guideline/staging/1643967181/lovastatin-Drug_Resource_Mappings.xlsx2022-02-04T17:33:07.000Z"88ae3d3732ef4491f658a22d74597a30"3897STANDARDdata/guideline/staging/1643967181/lovastatin_Pre_and_Post_Test_Alerts.xlsx2022-02-04T17:33:11.000Z"a593b137845c8de239efe312ddb6aaa5"4506STANDARDdata/guideline/staging/1643967181/pitavastatin recommendation.xlsx2022-02-04T17:33:10.000Z"be1063e41dd703c9e0bdc734803ad65b"6938STANDARDdata/guideline/staging/1643967181/pitavastatin-Drug_Resource_Mappings.xlsx2022-02-04T17:33:09.000Z"649f9a884d18ce182052a91a6aa78e87"3901STANDARDdata/guideline/staging/1643967181/pitavastatin_Pre_and_Post_Test_Alerts.xlsx2022-02-04T17:33:10.000Z"f212559bcf9e46d6be9c3a15f1cc310a"4507STANDARDdata/guideline/staging/1643967181/pravastatin recommendation.xlsx2022-02-04T17:33:09.000Z"4f39cf00020ec59be61485a4e5e9d71c"6938STANDARDdata/guideline/staging/1643967181/pravastatin_Pre_and_Post_Test_Alerts.xlsx2022-02-04T17:33:10.000Z"2732ae7d6aee21989b76145c6aa8f40d"4505STANDARDdata/guideline/staging/1643967181/rosuvastatin recommendation.xlsx2022-02-04T17:33:09.000Z"dcde8d4778dc9e62a0e41ad4f48c28a7"7935STANDARDdata/guideline/staging/1643967181/rosuvastatin_Pre_and_Post_Test_Alerts.xlsx2022-02-04T17:33:09.000Z"c5fef760d3feb279e7a0e4f5399c9084"4917STANDARDdata/guideline/staging/1752686345/2025-07-16T17:19:14.000Z"d41d8cd98f00b204e9800998ecf8427e"CRC64NVMEFULL_OBJECT0STANDARDdata/guideline/staging/1752686345/NAT2_Diplotype_Phenotype_Table.xlsx2025-07-16T17:19:17.000Z"3b75b2a10607140f12543711e7dd4bff"CRC64NVMEFULL_OBJECT44545STANDARDdata/guideline/staging/1752686345/NAT2_allele_definition_table.xlsx2025-07-16T17:19:17.000Z"6a0cefcc49b68371a217ebce43c6a3e7"CRC64NVMEFULL_OBJECT16211STANDARDdata/guideline/staging/1752686345/NAT2_allele_functionality_reference.xlsx2025-07-16T17:19:17.000Z"0e6f9bcdaba22b2b42727eff2ca0637e"CRC64NVMEFULL_OBJECT32378STANDARDdata/guideline/staging/1752686345/NAT2_consult.xlsx2025-07-16T17:19:17.000Z"d06b00e40a875d5a1bf4e3ea98bea4b6"CRC64NVMEFULL_OBJECT11692STANDARDdata/report/2020-08-19T22:01:27.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDdata/report/2020-10-01/allele_definition/CACNA1S-Allele_Definition_Table.xlsx2020-10-01T05:41:13.000Z"bf7b8ff2d7b1efaf26f6109c1c0edf76"5144STANDARDdata/report/2020-10-01/allele_definition/CFTR-Allele_Definition_Table.xlsx2020-10-01T05:41:13.000Z"ba2cc823a4d2cd14edf87bcc2afb695a"8784STANDARDdata/report/2020-10-01/allele_definition/CYP2B6-Allele_Definition_Table.xlsx2020-10-01T05:41:13.000Z"06d2b2c92c2eda19a34aed056d37855c"8673STANDARDdata/report/2020-10-01/allele_definition/CYP2C19-Allele_Definition_Table.xlsx2020-10-01T05:41:14.000Z"3c123ccdceb26941eb0632995d88f873"9236STANDARDdata/report/2020-10-01/allele_definition/CYP2C9-Allele_Definition_Table.xlsx2020-10-01T05:41:14.000Z"27be50a7a87aeb202e565c9002284609"10408STANDARDdata/report/2020-10-01/allele_definition/CYP2D6-Allele_Definition_Table.xlsx2020-10-01T05:41:15.000Z"009367626ba3264753c23f401dfb6959"18269STANDARDdata/report/2020-10-01/allele_definition/CYP3A5-Allele_Definition_Table.xlsx2020-10-01T05:41:15.000Z"d5e271bbab733d5e7c7f938225c8ae6c"6662STANDARDdata/report/2020-10-01/allele_definition/CYP4F2-Allele_Definition_Table.xlsx2020-10-01T05:41:15.000Z"19312e6d41e05c6b9c9b9e299e191909"5599STANDARDdata/report/2020-10-01/allele_definition/DPYD-Allele_Definition_Table.xlsx2020-10-01T05:41:16.000Z"37836b50ab56c97b77a2192ec75d38cb"12136STANDARDdata/report/2020-10-01/allele_definition/G6PD-Allele_Definition_Table.xlsx2020-10-01T05:41:16.000Z"c25235856718e3ef38fde07caddc6f9a"20305STANDARDdata/report/2020-10-01/allele_definition/IFNL3-Allele_Definition_Table.xlsx2020-10-01T05:41:16.000Z"5157ddeb6f39564ee1cf6c31393521e3"5146STANDARDdata/report/2020-10-01/allele_definition/NUDT15-Allele_Definition_Table.xlsx2020-10-01T05:41:17.000Z"a714ef029f0bbb2eaa97c3d23235f682"6957STANDARDdata/report/2020-10-01/allele_definition/RYR1-Allele_Definition_Table.xlsx2020-10-01T05:41:17.000Z"47a4cbd02ac298140f2071822a1d478e"8500STANDARDdata/report/2020-10-01/allele_definition/SLCO1B1-Allele_Definition_Table.xlsx2020-10-01T05:41:17.000Z"e335fa6a02ef21787a73ab457c8d325e"7803STANDARDdata/report/2020-10-01/allele_definition/TPMT-Allele_Definition_Table.xlsx2020-10-01T05:41:18.000Z"b8d7913e00cfcf1a9cb941dc41e0e005"8585STANDARDdata/report/2020-10-01/allele_definition/UGT1A1-Allele_Definition_Table.xlsx2020-10-01T05:41:18.000Z"680f3488ec6c23707c00e3189f39b86a"6325STANDARDdata/report/2020-10-01/allele_definition/VKORC1-Allele_Definition_Table.xlsx2020-10-01T05:41:18.000Z"b11f3d415af21d40499240407317b7a3"5134STANDARDdata/report/2020-10-01/allele_function_reference/CACNA1S-Allele_Functionality_Reference.xlsx2020-10-01T05:41:22.000Z"ea2d9037084f663ded964988d8b780fc"6237STANDARDdata/report/2020-10-01/allele_function_reference/CFTR-Allele_Functionality_Reference.xlsx2020-10-01T05:41:22.000Z"1e2e47a9d908b1ee8b04ebffc4248a69"6861STANDARDdata/report/2020-10-01/allele_function_reference/CYP2B6-Allele_Functionality_Reference.xlsx2020-10-01T05:41:22.000Z"f2d9e22ffe16dc15382c4887f9094bae"8586STANDARDdata/report/2020-10-01/allele_function_reference/CYP2C19-Allele_Functionality_Reference.xlsx2020-10-01T05:41:23.000Z"1bfd2a43522cdc1f6eb0f5b78429263e"9491STANDARDdata/report/2020-10-01/allele_function_reference/CYP2C9-Allele_Functionality_Reference.xlsx2020-10-01T05:41:23.000Z"f75acaf8d1b2da8db6ce6f10235901ab"20010STANDARDdata/report/2020-10-01/allele_function_reference/CYP2D6-Allele_Functionality_Reference.xlsx2020-10-01T05:41:23.000Z"5cd1aa23113255108fdc7f2eae7ffc32"14323STANDARDdata/report/2020-10-01/allele_function_reference/CYP3A5-Allele_Functionality_Reference.xlsx2020-10-01T05:41:24.000Z"19e5ac71a477e18e0d1edb7cc2eb62a9"5499STANDARDdata/report/2020-10-01/allele_function_reference/DPYD-Allele_Functionality_Reference.xlsx2020-10-01T05:41:24.000Z"87f97ce70dc19dfde5daed09ccfb9b16"9320STANDARDdata/report/2020-10-01/allele_function_reference/G6PD-Allele_Functionality_Reference.xlsx2020-10-01T05:41:24.000Z"6f1114c090b5959822d561fd17916bad"12761STANDARDdata/report/2020-10-01/allele_function_reference/NUDT15-Allele_Functionality_Reference.xlsx2020-10-01T05:41:25.000Z"12e44e79bb5f29b84ee09a67e9ecda82"5879STANDARDdata/report/2020-10-01/allele_function_reference/RYR1-Allele_Functionality_Reference.xlsx2020-10-01T05:41:25.000Z"04dedd24a931794551dc09a5ccf94674"13863STANDARDdata/report/2020-10-01/allele_function_reference/SLCO1B1-Allele_Functionality_Reference.xlsx2020-10-01T05:41:25.000Z"cac57930e3d6068354354fcf0bffc856"6959STANDARDdata/report/2020-10-01/allele_function_reference/TPMT-Allele_Functionality_Reference.xlsx2020-10-01T05:41:26.000Z"6b36816c45d1b55e6644bb39916dab02"6878STANDARDdata/report/2020-10-01/allele_function_reference/UGT1A1-Allele_Functionality_Reference.xlsx2020-10-01T05:41:26.000Z"8dec500c3982547b175ec7b95697fb82"5697STANDARDdata/report/2020-10-01/diplotype_phenotype/CACNA1S-Diplotype_Phenotype_Table.xlsx2020-10-01T05:43:06.000Z"b259cd318f2386a0c0578176ff270a39"5688STANDARDdata/report/2020-10-01/diplotype_phenotype/CYP2B6-Diplotype_Phenotype_Table.xlsx2020-10-01T05:43:06.000Z"2982cb99a5cc2f6c0b420609c61dd607"21383STANDARDdata/report/2020-10-01/diplotype_phenotype/CYP2C19-Diplotype_Phenotype_Table.xlsx2020-10-01T05:43:07.000Z"9a7b3974e38718e566187457e36dd5f8"19269STANDARDdata/report/2020-10-01/diplotype_phenotype/CYP2C9-Diplotype_Phenotype_Table.xlsx2020-10-01T05:43:07.000Z"28e3851819169c3df78af399590d1ad2"45842STANDARDdata/report/2020-10-01/diplotype_phenotype/CYP2D6-Diplotype_Phenotype_Table.xlsx2020-10-01T05:43:08.000Z"dbf3d7c622e73f9d4ba5efaa0d8d5e65"236232STANDARDdata/report/2020-10-01/diplotype_phenotype/CYP3A5-Diplotype_Phenotype_Table.xlsx2020-10-01T05:43:08.000Z"0190976fe1ef0a4d64094ba57f06c916"6564STANDARDdata/report/2020-10-01/diplotype_phenotype/DPYD-Diplotype_Phenotype_Table.xlsx2020-10-01T05:43:08.000Z"ef17da137915411179100e95efef8d68"81620STANDARDdata/report/2020-10-01/diplotype_phenotype/NUDT15-Diplotype_Phenotype_Table.xlsx2020-10-01T05:43:09.000Z"98ed23c80bc4a20054023f97b9a6c707"6644STANDARDdata/report/2020-10-01/diplotype_phenotype/RYR1-Diplotype_Phenotype_Table.xlsx2020-10-01T05:43:09.000Z"3d3a896e606ec189237df564ed916966"31001STANDARDdata/report/2020-10-01/diplotype_phenotype/SLCO1B1-Diplotype_Phenotype_Table.xlsx2020-10-01T05:43:09.000Z"186d53af79f1146523ef4036f27d8fbd"20459STANDARDdata/report/2020-10-01/diplotype_phenotype/TPMT-Diplotype_Phenotype_Table.xlsx2020-10-01T05:43:10.000Z"5ec5f5289f676103e14bf27970c0d558"24665STANDARDdata/report/2020-10-01/diplotype_phenotype/UGT1A1-Diplotype_Phenotype_Table.xlsx2020-10-01T05:43:10.000Z"045c9f67b14044e121cba9f2466225c4"6802STANDARDdata/report/2020-10-01/drug_resource/Ace Inhibitors, Plain-Drug_Resource_Mappings.xlsx2020-10-01T05:44:31.000Z"05eb75693ed730fe17d4368b33df717c"4446STANDARDdata/report/2020-10-01/drug_resource/Alkylating Agents-Drug_Resource_Mappings.xlsx2020-10-01T05:44:20.000Z"9ca5281aa330e1e83f1a1a1f57279c13"4443STANDARDdata/report/2020-10-01/drug_resource/Bisphosphonates-Drug_Resource_Mappings.xlsx2020-10-01T05:44:23.000Z"80f0f687fad49608adc4cee6cb7fce2d"4442STANDARDdata/report/2020-10-01/drug_resource/Platinum compounds-Drug_Resource_Mappings.xlsx2020-10-01T05:45:12.000Z"f71f4b2dc895f5648fbeb6602952e843"4444STANDARDdata/report/2020-10-01/drug_resource/Selective serotonin reuptake inhibitors-Drug_Resource_Mappings.xlsx2020-10-01T05:45:08.000Z"4231d35efb506d695950108349b3fde9"4456STANDARDdata/report/2020-10-01/drug_resource/Tumor necrosis factor alpha (TNF-alpha) inhibitors-Drug_Resource_Mappings.xlsx2020-10-01T05:45:23.000Z"9ee0fca74007f19171c39ef77ec4f9e4"4465STANDARDdata/report/2020-10-01/drug_resource/abacavir-Drug_Resource_Mappings.xlsx2020-10-01T05:45:28.000Z"72044a7742482aa149557cd61eb5ee1c"4459STANDARDdata/report/2020-10-01/drug_resource/aceclofenac-Drug_Resource_Mappings.xlsx2020-10-01T05:45:39.000Z"4588acd5b13d48202f3ff3b7573dc4e7"4453STANDARDdata/report/2020-10-01/drug_resource/acenocoumarol-Drug_Resource_Mappings.xlsx2020-10-01T05:44:26.000Z"90d254ea2b6b29b3ca2c151604e86f5c"4449STANDARDdata/report/2020-10-01/drug_resource/adalimumab-Drug_Resource_Mappings.xlsx2020-10-01T05:45:53.000Z"a5908678a11d701cc22c3941faba3baf"4450STANDARDdata/report/2020-10-01/drug_resource/alendronate-Drug_Resource_Mappings.xlsx2020-10-01T05:45:42.000Z"b49c927321c80dc33ea645b07bd76701"4447STANDARDdata/report/2020-10-01/drug_resource/alfentanil-Drug_Resource_Mappings.xlsx2020-10-01T05:44:30.000Z"74eb565f3ed7b6d2a589c6bd9df40f28"4443STANDARDdata/report/2020-10-01/drug_resource/allopurinol-Drug_Resource_Mappings.xlsx2020-10-01T05:45:28.000Z"447680a43a78ee9495e9d5ef592bc974"4454STANDARDdata/report/2020-10-01/drug_resource/amifampridine phosphate-Drug_Resource_Mappings.xlsx2020-10-01T05:45:41.000Z"b7d0e92978f9165cfca14dd4c0d866cb"4453STANDARDdata/report/2020-10-01/drug_resource/amifampridine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:30.000Z"4a5da48e1e538d2cf53d90f509a666fb"4455STANDARDdata/report/2020-10-01/drug_resource/amikacin-Drug_Resource_Mappings.xlsx2020-10-01T05:45:51.000Z"220b0d598602d4c5532f00a29c403d88"4463STANDARDdata/report/2020-10-01/drug_resource/aminoglycoside antibacterials-Drug_Resource_Mappings.xlsx2020-10-01T05:44:31.000Z"52dc83ad95245436c227c54ae8437989"4448STANDARDdata/report/2020-10-01/drug_resource/amisulpride-Drug_Resource_Mappings.xlsx2020-10-01T05:45:53.000Z"da39a05cf31a7bffc67c4e77d86159e1"4449STANDARDdata/report/2020-10-01/drug_resource/amitriptyline-Drug_Resource_Mappings.xlsx2020-10-01T05:45:25.000Z"e5ba0f4aaac14d55a58e2f0d8363958c"4452STANDARDdata/report/2020-10-01/drug_resource/amoxapine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:45.000Z"01a242fb52a9962da4c6af022f2534e6"4445STANDARDdata/report/2020-10-01/drug_resource/amphetamine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:52.000Z"f90ba842dbf45d082138552211c6e00f"4445STANDARDdata/report/2020-10-01/drug_resource/anthracyclines and related substances-Drug_Resource_Mappings.xlsx2020-10-01T05:44:24.000Z"bd3a422a2db8b3bd50e2603178411bc9"4454STANDARDdata/report/2020-10-01/drug_resource/antidepressants-Drug_Resource_Mappings.xlsx2020-10-01T05:44:26.000Z"fcd49f7d451cbc4882871d3795f69e91"4437STANDARDdata/report/2020-10-01/drug_resource/antipsychotics-Drug_Resource_Mappings.xlsx2020-10-01T05:44:20.000Z"aef378f741e73c2082f2e30914dfaf08"4437STANDARDdata/report/2020-10-01/drug_resource/aripiprazole lauroxil-Drug_Resource_Mappings.xlsx2020-10-01T05:45:43.000Z"9fcf0ddd94e86abf474c8f48bd6d4929"4459STANDARDdata/report/2020-10-01/drug_resource/aripiprazole-Drug_Resource_Mappings.xlsx2020-10-01T05:44:30.000Z"1fb467d0dc9a9823e5c09d9276fc2931"4448STANDARDdata/report/2020-10-01/drug_resource/aspirin-Drug_Resource_Mappings.xlsx2020-10-01T05:44:36.000Z"ae8a585295acd91c67d8154a66bfc985"4459STANDARDdata/report/2020-10-01/drug_resource/ataluren-Drug_Resource_Mappings.xlsx2020-10-01T05:44:22.000Z"2f84645e775af09e63c1c88bff28f3cb"4439STANDARDdata/report/2020-10-01/drug_resource/atazanavir-Drug_Resource_Mappings.xlsx2020-10-01T05:45:16.000Z"d4755e3c8f0a29b8bd6a2cb9982ecc6b"4454STANDARDdata/report/2020-10-01/drug_resource/atenolol-Drug_Resource_Mappings.xlsx2020-10-01T05:45:43.000Z"270c5fbb9f601412ba800ffa89cd09de"4446STANDARDdata/report/2020-10-01/drug_resource/atomoxetine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:24.000Z"ef161ec325f48db66b209159c3b5fdb6"4449STANDARDdata/report/2020-10-01/drug_resource/atorvastatin-Drug_Resource_Mappings.xlsx2020-10-01T05:44:33.000Z"da4718719f05cc355916e3e464858964"4448STANDARDdata/report/2020-10-01/drug_resource/avatrombopag-Drug_Resource_Mappings.xlsx2020-10-01T05:45:54.000Z"751fa4a89190022b5d7d0086ce875581"4457STANDARDdata/report/2020-10-01/drug_resource/azathioprine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:17.000Z"d351e112e7b6963ea70e2ceac739d0b0"4450STANDARDdata/report/2020-10-01/drug_resource/belinostat-Drug_Resource_Mappings.xlsx2020-10-01T05:44:19.000Z"717ab769f5029188f33e607de89d5430"4447STANDARDdata/report/2020-10-01/drug_resource/brexpiprazole-Drug_Resource_Mappings.xlsx2020-10-01T05:44:28.000Z"1ced9e3f0e8a1e7c872e64d7d783203b"4451STANDARDdata/report/2020-10-01/drug_resource/brivaracetam-Drug_Resource_Mappings.xlsx2020-10-01T05:44:21.000Z"2c9e77fd9bcd12f60c6eead8b1ac8a6d"4449STANDARDdata/report/2020-10-01/drug_resource/bucindolol-Drug_Resource_Mappings.xlsx2020-10-01T05:45:55.000Z"caa4e47a4f6b5ecf35b79400e69e32c4"4448STANDARDdata/report/2020-10-01/drug_resource/budesonide-Drug_Resource_Mappings.xlsx2020-10-01T05:44:28.000Z"9de0507115d136a32e035910c48cbfc5"4468STANDARDdata/report/2020-10-01/drug_resource/bupropion-Drug_Resource_Mappings.xlsx2020-10-01T05:44:31.000Z"6dd0a6397b61534a16fc8cd650886772"4446STANDARDdata/report/2020-10-01/drug_resource/caffeine-Drug_Resource_Mappings.xlsx2020-10-01T05:44:23.000Z"a729a9b7bf71f5a01aa3f35f27ac81e1"4443STANDARDdata/report/2020-10-01/drug_resource/capecitabine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:15.000Z"095964160ea4623e267a3373a36d400c"4449STANDARDdata/report/2020-10-01/drug_resource/captopril-Drug_Resource_Mappings.xlsx2020-10-01T05:44:29.000Z"0cb8c594a74a832d9ac23a12549600bb"4446STANDARDdata/report/2020-10-01/drug_resource/carbamazepine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:14.000Z"e94663ef7970ab5c309b02ae04703d79"4447STANDARDdata/report/2020-10-01/drug_resource/carbimazole-Drug_Resource_Mappings.xlsx2020-10-01T05:44:18.000Z"4cd59943da9ab06efd4ccd74ec5fd25e"4451STANDARDdata/report/2020-10-01/drug_resource/carboplatin-Drug_Resource_Mappings.xlsx2020-10-01T05:44:25.000Z"151e8d201cbde93ec47b95cd7155a693"4449STANDARDdata/report/2020-10-01/drug_resource/carglumic acid-Drug_Resource_Mappings.xlsx2020-10-01T05:44:29.000Z"d13e8e58dfa95b72cdb7b3e68753c206"4454STANDARDdata/report/2020-10-01/drug_resource/carisoprodol-Drug_Resource_Mappings.xlsx2020-10-01T05:44:27.000Z"e361c399658647b64d8eaa12d6e4255a"4448STANDARDdata/report/2020-10-01/drug_resource/carvedilol-Drug_Resource_Mappings.xlsx2020-10-01T05:44:35.000Z"39a37cdf69e9f5b08facb7f1784b4974"4448STANDARDdata/report/2020-10-01/drug_resource/celecoxib-Drug_Resource_Mappings.xlsx2020-10-01T05:45:20.000Z"ef62b5e771c1ca7932ce27e9362f8034"4458STANDARDdata/report/2020-10-01/drug_resource/cerivastatin-Drug_Resource_Mappings.xlsx2020-10-01T05:44:36.000Z"4b972f97fc448ebef7e7e43c397f4b6d"4451STANDARDdata/report/2020-10-01/drug_resource/cetuximab-Drug_Resource_Mappings.xlsx2020-10-01T05:44:26.000Z"8686451d691a2896f2e4871c77adaac9"4447STANDARDdata/report/2020-10-01/drug_resource/cevimeline-Drug_Resource_Mappings.xlsx2020-10-01T05:44:22.000Z"9205b62f1e8a9f9634f39ffa6a710161"4449STANDARDdata/report/2020-10-01/drug_resource/chloramphenicol-Drug_Resource_Mappings.xlsx2020-10-01T05:44:34.000Z"05d35c6a35d73fcc09fc95bff114f9d8"4484STANDARDdata/report/2020-10-01/drug_resource/chloroquine-Drug_Resource_Mappings.xlsx2020-10-01T05:44:28.000Z"45b7d9165f8916823c623f21c33a6c39"4446STANDARDdata/report/2020-10-01/drug_resource/chlorpropamide-Drug_Resource_Mappings.xlsx2020-10-01T05:44:23.000Z"9044208e681c3ace60e18f1f512df133"4448STANDARDdata/report/2020-10-01/drug_resource/ciprofloxacin-Drug_Resource_Mappings.xlsx2020-10-01T05:44:35.000Z"aa4a2fe8eb1f321fe60103dbfedc9e53"4467STANDARDdata/report/2020-10-01/drug_resource/cisplatin-Drug_Resource_Mappings.xlsx2020-10-01T05:44:32.000Z"d6266d0bd2581b2ee703dc723761ecf4"4448STANDARDdata/report/2020-10-01/drug_resource/citalopram-Drug_Resource_Mappings.xlsx2020-10-01T05:45:24.000Z"fc36164389c31b3764bffe5aa6d44290"4446STANDARDdata/report/2020-10-01/drug_resource/clobazam-Drug_Resource_Mappings.xlsx2020-10-01T05:44:29.000Z"08935beec45ff65471d97372df700466"4445STANDARDdata/report/2020-10-01/drug_resource/clomipramine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:20.000Z"841bb45a9db10953b1bb10c16480aeea"4447STANDARDdata/report/2020-10-01/drug_resource/clopidogrel-Drug_Resource_Mappings.xlsx2020-10-01T05:45:24.000Z"67cc9f959fdc414caf1f0c7d7a902744"4449STANDARDdata/report/2020-10-01/drug_resource/clozapine-Drug_Resource_Mappings.xlsx2020-10-01T05:44:33.000Z"39acbfb8787b12c202d46676d34e18ba"4446STANDARDdata/report/2020-10-01/drug_resource/codeine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:41.000Z"776fc8734bcd36e64f6eb933db7e2dbd"4458STANDARDdata/report/2020-10-01/drug_resource/cyclophosphamide-Drug_Resource_Mappings.xlsx2020-10-01T05:44:21.000Z"60dd8be3ac89823d91713f75561c6f1c"4450STANDARDdata/report/2020-10-01/drug_resource/cyclosporine-Drug_Resource_Mappings.xlsx2020-10-01T05:44:32.000Z"b62fa956a975ad18e3eaace6a05e84d7"4454STANDARDdata/report/2020-10-01/drug_resource/dabrafenib-Drug_Resource_Mappings.xlsx2020-10-01T05:44:33.000Z"d0f9164a1a5db919f466383d4ac9fb4f"4447STANDARDdata/report/2020-10-01/drug_resource/dapsone-Drug_Resource_Mappings.xlsx2020-10-01T05:44:34.000Z"91bcff38d22691e573383d7da4092357"4452STANDARDdata/report/2020-10-01/drug_resource/darifenacin-Drug_Resource_Mappings.xlsx2020-10-01T05:44:19.000Z"23b2400a09ce781c68bca3de67eb3a1c"4453STANDARDdata/report/2020-10-01/drug_resource/daunorubicin-Drug_Resource_Mappings.xlsx2020-10-01T05:45:42.000Z"f978a9b8bf3ea1bc99df3ec309b5daef"4447STANDARDdata/report/2020-10-01/drug_resource/desflurane-Drug_Resource_Mappings.xlsx2020-10-01T05:45:37.000Z"373dcf1f9ccce58ea0fb781dae55d890"4450STANDARDdata/report/2020-10-01/drug_resource/desipramine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:37.000Z"74c7f8544403d4d234646b4457fd34d8"4447STANDARDdata/report/2020-10-01/drug_resource/deutetrabenazine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:45.000Z"6b359f82c15ef5d93d4ce47eea209e8e"4453STANDARDdata/report/2020-10-01/drug_resource/dexlansoprazole-Drug_Resource_Mappings.xlsx2020-10-01T05:44:36.000Z"d7d511a91903c4633034229c4705e770"4455STANDARDdata/report/2020-10-01/drug_resource/dextromethorphan-Drug_Resource_Mappings.xlsx2020-10-01T05:44:20.000Z"e15f2892c65b6fc21a1a302c155cf66d"4452STANDARDdata/report/2020-10-01/drug_resource/diazepam-Drug_Resource_Mappings.xlsx2020-10-01T05:44:25.000Z"e4d0855b126a56c53f91ab933b3b1b6e"4445STANDARDdata/report/2020-10-01/drug_resource/diclofenac-Drug_Resource_Mappings.xlsx2020-10-01T05:44:18.000Z"cbb0458025b162c918f7392888f1e5da"4469STANDARDdata/report/2020-10-01/drug_resource/digoxin-Drug_Resource_Mappings.xlsx2020-10-01T05:44:25.000Z"8b20e06fa262d80685bdb92d26669576"4444STANDARDdata/report/2020-10-01/drug_resource/dimercaprol-Drug_Resource_Mappings.xlsx2020-10-01T05:44:21.000Z"9ec08a365c47a1442c79004edd8777e3"4453STANDARDdata/report/2020-10-01/drug_resource/divalproex sodium-Drug_Resource_Mappings.xlsx2020-10-01T05:44:35.000Z"ba09533eb6de634b519540d310f9b60d"4454STANDARDdata/report/2020-10-01/drug_resource/dolasetron-Drug_Resource_Mappings.xlsx2020-10-01T05:44:24.000Z"47c58dc11f604585291870daf9729508"4448STANDARDdata/report/2020-10-01/drug_resource/dolutegravir-Drug_Resource_Mappings.xlsx2020-10-01T05:44:27.000Z"66edb984ec562868f3a2ef407d544e62"4450STANDARDdata/report/2020-10-01/drug_resource/donepezil-Drug_Resource_Mappings.xlsx2020-10-01T05:44:40.000Z"884c3dcf6f6b75bf503a38be045a498a"4449STANDARDdata/report/2020-10-01/drug_resource/doxepin-Drug_Resource_Mappings.xlsx2020-10-01T05:45:40.000Z"cc0b2bddac5ebf6155ccc46ed2bf124f"4445STANDARDdata/report/2020-10-01/drug_resource/doxorubicin-Drug_Resource_Mappings.xlsx2020-10-01T05:45:57.000Z"9856b4375bdb425932f30bb3b66939bf"4449STANDARDdata/report/2020-10-01/drug_resource/dronabinol-Drug_Resource_Mappings.xlsx2020-10-01T05:45:44.000Z"dbaa5b808ee431f8951bc4ceafb5298e"4448STANDARDdata/report/2020-10-01/drug_resource/duloxetine-Drug_Resource_Mappings.xlsx2020-10-01T05:44:50.000Z"68d3b8861d2a7a9624d5b3dc71044e04"4447STANDARDdata/report/2020-10-01/drug_resource/efavirenz-Drug_Resource_Mappings.xlsx2020-10-01T05:45:35.000Z"f2dcbe38214eba16339286e1e46a10c0"4451STANDARDdata/report/2020-10-01/drug_resource/elagolix-Drug_Resource_Mappings.xlsx2020-10-01T05:45:42.000Z"0f4258dff98130a1f634108af9c3c186"4448STANDARDdata/report/2020-10-01/drug_resource/eliglustat-Drug_Resource_Mappings.xlsx2020-10-01T05:44:47.000Z"ed0b9e368464cffc8c7cf7544796d6de"4447STANDARDdata/report/2020-10-01/drug_resource/eltrombopag-Drug_Resource_Mappings.xlsx2020-10-01T05:44:44.000Z"a6c45e5253983c5faa7d568ea7db61ab"4449STANDARDdata/report/2020-10-01/drug_resource/enflurane-Drug_Resource_Mappings.xlsx2020-10-01T05:45:39.000Z"14959125d9f7982944c0f561ef17c534"4445STANDARDdata/report/2020-10-01/drug_resource/epirubicin-Drug_Resource_Mappings.xlsx2020-10-01T05:44:51.000Z"52a3c663cfd48cd0c4a230334957dccd"4448STANDARDdata/report/2020-10-01/drug_resource/erdafitinib-Drug_Resource_Mappings.xlsx2020-10-01T05:45:56.000Z"02834c135419a854086aacf9d438fbbe"4450STANDARDdata/report/2020-10-01/drug_resource/erythromycin-Drug_Resource_Mappings.xlsx2020-10-01T05:44:47.000Z"35d639c9d3034a52007875102a61e7ea"4463STANDARDdata/report/2020-10-01/drug_resource/escitalopram-Drug_Resource_Mappings.xlsx2020-10-01T05:45:29.000Z"6fe3f173926f388be6552b1a25af76d3"4449STANDARDdata/report/2020-10-01/drug_resource/esomeprazole-Drug_Resource_Mappings.xlsx2020-10-01T05:44:38.000Z"4e78165ab0062a2684b6bd73582be1cc"4450STANDARDdata/report/2020-10-01/drug_resource/etanercept-Drug_Resource_Mappings.xlsx2020-10-01T05:45:51.000Z"6b615fe27f0e0a70baf9b8c9ecb36c76"4447STANDARDdata/report/2020-10-01/drug_resource/ethanol-Drug_Resource_Mappings.xlsx2020-10-01T05:44:49.000Z"c800454de6d548344443ac7a2f24c51d"4457STANDARDdata/report/2020-10-01/drug_resource/etoposide-Drug_Resource_Mappings.xlsx2020-10-01T05:44:46.000Z"590bbdaa3d3496d5d957c16a4b1367f0"4445STANDARDdata/report/2020-10-01/drug_resource/fentanyl-Drug_Resource_Mappings.xlsx2020-10-01T05:44:43.000Z"c33006e10261bb20b0a91a2f09ff3277"4454STANDARDdata/report/2020-10-01/drug_resource/fesoterodine-Drug_Resource_Mappings.xlsx2020-10-01T05:44:52.000Z"1c8aeb5685cfd42f2490ae966a58e0fd"4451STANDARDdata/report/2020-10-01/drug_resource/flecainide-Drug_Resource_Mappings.xlsx2020-10-01T05:44:40.000Z"d90e0f0e09326d0531e0d16b6a4b80fa"4445STANDARDdata/report/2020-10-01/drug_resource/flibanserin-Drug_Resource_Mappings.xlsx2020-10-01T05:44:45.000Z"36c51a4abeab717ca06118845be785bd"4447STANDARDdata/report/2020-10-01/drug_resource/fluorouracil-Drug_Resource_Mappings.xlsx2020-10-01T05:45:14.000Z"61a74e8e18fe992b417ab2d7d635c875"4456STANDARDdata/report/2020-10-01/drug_resource/fluoxetine-Drug_Resource_Mappings.xlsx2020-10-01T05:44:53.000Z"6ed37971052e9701bee7378c19cb8ab2"4442STANDARDdata/report/2020-10-01/drug_resource/flurbiprofen-Drug_Resource_Mappings.xlsx2020-10-01T05:45:34.000Z"7e02efccd623eb23dc711dc7448f9cc1"4475STANDARDdata/report/2020-10-01/drug_resource/fluticasone propionate-Drug_Resource_Mappings.xlsx2020-10-01T05:44:44.000Z"cd323241f3c3e99f5733fc67c7080dea"4469STANDARDdata/report/2020-10-01/drug_resource/fluticasone_salmeterol-Drug_Resource_Mappings.xlsx2020-10-01T05:44:38.000Z"1cfa04c8cc910d2ffe9fe60a6cafbac5"4454STANDARDdata/report/2020-10-01/drug_resource/fluvastatin-Drug_Resource_Mappings.xlsx2020-10-01T05:45:49.000Z"336a5f3b0100e3363e9a5d53f1b6f458"4449STANDARDdata/report/2020-10-01/drug_resource/fluvoxamine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:37.000Z"a69d3a203ef0ffa4004135bef4c35d59"4450STANDARDdata/report/2020-10-01/drug_resource/fosphenytoin-Drug_Resource_Mappings.xlsx2020-10-01T05:45:07.000Z"c2fbea6d9df88d4d89ef7d4815bfc84a"4453STANDARDdata/report/2020-10-01/drug_resource/furosemide-Drug_Resource_Mappings.xlsx2020-10-01T05:44:40.000Z"4575dc2786b93e2f16078ab5da074471"4447STANDARDdata/report/2020-10-01/drug_resource/galantamine-Drug_Resource_Mappings.xlsx2020-10-01T05:44:47.000Z"6270a01b3dc5de19610acdf47bb3380a"4447STANDARDdata/report/2020-10-01/drug_resource/gefitinib-Drug_Resource_Mappings.xlsx2020-10-01T05:45:47.000Z"4483f0d82e5f4f720ddacc8f0fef4791"4452STANDARDdata/report/2020-10-01/drug_resource/gemcitabine-Drug_Resource_Mappings.xlsx2020-10-01T05:44:49.000Z"c72fb99ad8391babbba90798fdd3a20e"4447STANDARDdata/report/2020-10-01/drug_resource/gentamicin-Drug_Resource_Mappings.xlsx2020-10-01T05:45:53.000Z"55d0f4ef67d8b1800033ca73195ffc5d"4471STANDARDdata/report/2020-10-01/drug_resource/glibenclamide-Drug_Resource_Mappings.xlsx2020-10-01T05:44:50.000Z"ab15ee38772222ec4f0b52deab085211"4448STANDARDdata/report/2020-10-01/drug_resource/glimepiride-Drug_Resource_Mappings.xlsx2020-10-01T05:44:52.000Z"f7dcd5afeff171414444131c36f1c07d"4448STANDARDdata/report/2020-10-01/drug_resource/glipizide-Drug_Resource_Mappings.xlsx2020-10-01T05:44:53.000Z"de70dd9cafead33b1814e253536c5833"4446STANDARDdata/report/2020-10-01/drug_resource/haloperidol-Drug_Resource_Mappings.xlsx2020-10-01T05:44:41.000Z"9ac092b24e11303fd2e24c9070fe4b05"4446STANDARDdata/report/2020-10-01/drug_resource/halothane-Drug_Resource_Mappings.xlsx2020-10-01T05:45:30.000Z"540b9c4a3444ac23b7d24919f44f4303"4443STANDARDdata/report/2020-10-01/drug_resource/hmg coa reductase inhibitors-Drug_Resource_Mappings.xlsx2020-10-01T05:44:45.000Z"6ad728653de47dbc4b1644f8dffe21ac"4452STANDARDdata/report/2020-10-01/drug_resource/hormonal contraceptives for systemic use-Drug_Resource_Mappings.xlsx2020-10-01T05:44:43.000Z"171a41b10faf7a2281f63ca670a467cc"4455STANDARDdata/report/2020-10-01/drug_resource/hydralazine-Drug_Resource_Mappings.xlsx2020-10-01T05:44:49.000Z"986e168b08aee8bb6e68ec4f03fc0fe4"4448STANDARDdata/report/2020-10-01/drug_resource/hydrochlorothiazide-Drug_Resource_Mappings.xlsx2020-10-01T05:44:41.000Z"4a1a02100c97994a40ddf498451bef03"4491STANDARDdata/report/2020-10-01/drug_resource/hydrocodone-Drug_Resource_Mappings.xlsx2020-10-01T05:45:47.000Z"d45fea3a81817b88d3b88160f1eb076c"4448STANDARDdata/report/2020-10-01/drug_resource/hydroxychloroquine-Drug_Resource_Mappings.xlsx2020-10-01T05:44:48.000Z"b5de2d1f4ba43e9a0170a54b860fbe43"4456STANDARDdata/report/2020-10-01/drug_resource/ibuprofen-Drug_Resource_Mappings.xlsx2020-10-01T05:45:57.000Z"bc1cad375e2420bb5debe4b7a7c2d673"4468STANDARDdata/report/2020-10-01/drug_resource/idarubicin-Drug_Resource_Mappings.xlsx2020-10-01T05:45:43.000Z"64cf10e82c6c1c51d8b5cbb4d4eeb587"4448STANDARDdata/report/2020-10-01/drug_resource/iloperidone-Drug_Resource_Mappings.xlsx2020-10-01T05:44:48.000Z"07c146522ae3c02a535f29e3f9d9349f"4446STANDARDdata/report/2020-10-01/drug_resource/imipramine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:40.000Z"4eeb94db843e4661dab59f4c1179a8b8"4445STANDARDdata/report/2020-10-01/drug_resource/indomethacin-Drug_Resource_Mappings.xlsx2020-10-01T05:45:32.000Z"cfc4542c9617911f05cfaf3dced7228f"4450STANDARDdata/report/2020-10-01/drug_resource/infliximab-Drug_Resource_Mappings.xlsx2020-10-01T05:45:46.000Z"7c4544fcd011bc9c99eedd09a7a751bf"4450STANDARDdata/report/2020-10-01/drug_resource/interferon alfa-2b, recombinant-Drug_Resource_Mappings.xlsx2020-10-01T05:44:37.000Z"26c09a08b539286bee05770eb678becb"4461STANDARDdata/report/2020-10-01/drug_resource/irinotecan-Drug_Resource_Mappings.xlsx2020-10-01T05:44:53.000Z"78aebff8a452a7764de1614ba4913840"4447STANDARDdata/report/2020-10-01/drug_resource/isoflurane-Drug_Resource_Mappings.xlsx2020-10-01T05:45:38.000Z"851af3d5de276a2efee4ec37c0e4122e"4445STANDARDdata/report/2020-10-01/drug_resource/isoniazid-Drug_Resource_Mappings.xlsx2020-10-01T05:44:46.000Z"efc9c20b8e55675090a84aa146b5e146"4448STANDARDdata/report/2020-10-01/drug_resource/isosorbide dinitrate-Drug_Resource_Mappings.xlsx2020-10-01T05:44:52.000Z"c4574caacfb15ff2635eb5792a333f58"4459STANDARDdata/report/2020-10-01/drug_resource/ivacaftor-Drug_Resource_Mappings.xlsx2020-10-01T05:44:54.000Z"4e6b2d0e6a1cfd873b4ecd0fa4021bd1"4455STANDARDdata/report/2020-10-01/drug_resource/kanamycin-Drug_Resource_Mappings.xlsx2020-10-01T05:45:56.000Z"93a696abd376a6824dedd32ee4f4020f"4463STANDARDdata/report/2020-10-01/drug_resource/l-methylfolate-Drug_Resource_Mappings.xlsx2020-10-01T05:45:41.000Z"2c868cd565e3bd9a31752a7d4cd669e9"4452STANDARDdata/report/2020-10-01/drug_resource/labetalol-Drug_Resource_Mappings.xlsx2020-10-01T05:45:52.000Z"5b3e2baaea8de6fdde7ac6f182290b9c"4451STANDARDdata/report/2020-10-01/drug_resource/lamotrigine-Drug_Resource_Mappings.xlsx2020-10-01T05:44:43.000Z"a12d5700de35a8f377faadc9fdff307c"4448STANDARDdata/report/2020-10-01/drug_resource/lansoprazole-Drug_Resource_Mappings.xlsx2020-10-01T05:44:54.000Z"edc393de604705114ef254ce0b1dbeca"4451STANDARDdata/report/2020-10-01/drug_resource/lapatinib-Drug_Resource_Mappings.xlsx2020-10-01T05:44:46.000Z"cd210922540a11976c852f16f4a43557"4452STANDARDdata/report/2020-10-01/drug_resource/latanoprost-Drug_Resource_Mappings.xlsx2020-10-01T05:44:39.000Z"e1733e3816e987a7d55592fb9408c332"4452STANDARDdata/report/2020-10-01/drug_resource/lesinurad-Drug_Resource_Mappings.xlsx2020-10-01T05:44:42.000Z"cbd84f0326c731dfd1047a2e446e1303"4446STANDARDdata/report/2020-10-01/drug_resource/leucovorin-Drug_Resource_Mappings.xlsx2020-10-01T05:44:51.000Z"dddfd66985216c2c9fddeb0071f8430d"4446STANDARDdata/report/2020-10-01/drug_resource/levofloxacin-Drug_Resource_Mappings.xlsx2020-10-01T05:44:38.000Z"2246ae5c967066756c66dafe93a0c6b8"4457STANDARDdata/report/2020-10-01/drug_resource/lidocaine-Drug_Resource_Mappings.xlsx2020-10-01T05:44:45.000Z"9589d1d45792a2a402bdb355fd16522e"4479STANDARDdata/report/2020-10-01/drug_resource/lofexidine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:49.000Z"0643941dd9d441aa0c2c1ddc3a4fc1dd"4452STANDARDdata/report/2020-10-01/drug_resource/lornoxicam-Drug_Resource_Mappings.xlsx2020-10-01T05:45:39.000Z"ee4bc571153e5aff9230c70e1e861a1b"4453STANDARDdata/report/2020-10-01/drug_resource/lumiracoxib-Drug_Resource_Mappings.xlsx2020-10-01T05:45:35.000Z"360633403c55c082163b978f1ce11535"4450STANDARDdata/report/2020-10-01/drug_resource/mafenide-Drug_Resource_Mappings.xlsx2020-10-01T05:44:42.000Z"326bffc0689f1af66f56e2921a72c489"4441STANDARDdata/report/2020-10-01/drug_resource/meclizine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:49.000Z"1df4c05112a8d2259d1eb5fff1fe93e4"4447STANDARDdata/report/2020-10-01/drug_resource/mefloquine-Drug_Resource_Mappings.xlsx2020-10-01T05:44:39.000Z"2c5a00cd869e8c7b062da6a83ebfec23"4447STANDARDdata/report/2020-10-01/drug_resource/meloxicam-Drug_Resource_Mappings.xlsx2020-10-01T05:45:13.000Z"a018a1c69f34b723448c3c07378db2fb"4445STANDARDdata/report/2020-10-01/drug_resource/mercaptopurine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:19.000Z"8c8cb865a3de538fa24f8d55c34c96ed"4448STANDARDdata/report/2020-10-01/drug_resource/mesalazine-Drug_Resource_Mappings.xlsx2020-10-01T05:44:51.000Z"3e4fefc8e2b1326051dd1063f1a65032"4447STANDARDdata/report/2020-10-01/drug_resource/metamizole-Drug_Resource_Mappings.xlsx2020-10-01T05:45:00.000Z"a51bb7a2585ed8f521ac253b93c08a6a"4449STANDARDdata/report/2020-10-01/drug_resource/metformin-Drug_Resource_Mappings.xlsx2020-10-01T05:44:41.000Z"b0a324e0c9fe50801d1238ed573b5cb6"4446STANDARDdata/report/2020-10-01/drug_resource/methadone-Drug_Resource_Mappings.xlsx2020-10-01T05:44:42.000Z"783075b7b513fb3de235115a7636680f"4446STANDARDdata/report/2020-10-01/drug_resource/methazolamide-Drug_Resource_Mappings.xlsx2020-10-01T05:44:50.000Z"0f40d3ee26826ae6b457a509ee7763ce"4448STANDARDdata/report/2020-10-01/drug_resource/methimazole-Drug_Resource_Mappings.xlsx2020-10-01T05:44:44.000Z"a4560d42aa507028d6c3aaee01cb59a6"4446STANDARDdata/report/2020-10-01/drug_resource/methotrexate-Drug_Resource_Mappings.xlsx2020-10-01T05:44:37.000Z"7d2af9d753c82eb15f569f3ea0aa4abe"4452STANDARDdata/report/2020-10-01/drug_resource/methoxyflurane-Drug_Resource_Mappings.xlsx2020-10-01T05:45:33.000Z"743f0b7087fe339f3dbaef118e85aed8"4450STANDARDdata/report/2020-10-01/drug_resource/methylene blue-Drug_Resource_Mappings.xlsx2020-10-01T05:45:04.000Z"484723df9572c7b042a082825e1a9737"4450STANDARDdata/report/2020-10-01/drug_resource/methylphenidate-Drug_Resource_Mappings.xlsx2020-10-01T05:44:56.000Z"c5b265d4a1e0a7ffe1cbb8d3cc5e439b"4450STANDARDdata/report/2020-10-01/drug_resource/metoclopramide-Drug_Resource_Mappings.xlsx2020-10-01T05:44:56.000Z"2a9661e1bb3b1f3d7b2df9cc045b9aef"4450STANDARDdata/report/2020-10-01/drug_resource/metoprolol-Drug_Resource_Mappings.xlsx2020-10-01T05:45:04.000Z"bb2be410686fdd43834137e3a3903b58"4448STANDARDdata/report/2020-10-01/drug_resource/midazolam-Drug_Resource_Mappings.xlsx2020-10-01T05:45:11.000Z"7aba162ef81daced3b312591081be39c"4446STANDARDdata/report/2020-10-01/drug_resource/mirabegron-Drug_Resource_Mappings.xlsx2020-10-01T05:45:44.000Z"d3e533d0fac429ab716f9dd5e21c555f"4451STANDARDdata/report/2020-10-01/drug_resource/mirtazapine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:02.000Z"9061434aa0e4900841e63398f2c55bf9"4449STANDARDdata/report/2020-10-01/drug_resource/mivacurium-Drug_Resource_Mappings.xlsx2020-10-01T05:45:55.000Z"425c17c7ced6b78dfe70bf1e77d9c056"4445STANDARDdata/report/2020-10-01/drug_resource/modafinil-Drug_Resource_Mappings.xlsx2020-10-01T05:44:59.000Z"9fe6f3b6ea80a96e6b9bb0527455942e"4444STANDARDdata/report/2020-10-01/drug_resource/morphine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:12.000Z"9b724690dd0ee5877b130ca2a7172705"4443STANDARDdata/report/2020-10-01/drug_resource/moxifloxacin-Drug_Resource_Mappings.xlsx2020-10-01T05:45:01.000Z"9bbe5d367a1bb0a9812a1c4edfa7a747"4459STANDARDdata/report/2020-10-01/drug_resource/mycophenolic acid-Drug_Resource_Mappings.xlsx2020-10-01T05:45:07.000Z"2af0c685e7958dd05017417046ce75bb"4456STANDARDdata/report/2020-10-01/drug_resource/nabumetone-Drug_Resource_Mappings.xlsx2020-10-01T05:45:08.000Z"eb9800ae4a32938488a44a928426d7f0"4448STANDARDdata/report/2020-10-01/drug_resource/nalidixic acid-Drug_Resource_Mappings.xlsx2020-10-01T05:45:12.000Z"c80e6fbf1ba2ea59449a2d3535433169"4456STANDARDdata/report/2020-10-01/drug_resource/naloxone-Drug_Resource_Mappings.xlsx2020-10-01T05:44:57.000Z"2dfaff63d8d944474f460631503115f3"4445STANDARDdata/report/2020-10-01/drug_resource/naltrexone-Drug_Resource_Mappings.xlsx2020-10-01T05:45:06.000Z"0c8383e99744914920dfbab4cfb7dad0"4444STANDARDdata/report/2020-10-01/drug_resource/naproxen-Drug_Resource_Mappings.xlsx2020-10-01T05:44:55.000Z"7a712bb3180bc1ff4ca292f4a8513b6d"4446STANDARDdata/report/2020-10-01/drug_resource/nebivolol-Drug_Resource_Mappings.xlsx2020-10-01T05:45:48.000Z"4d75cafb0761e8f1dc3a3cbf9a32bd35"4452STANDARDdata/report/2020-10-01/drug_resource/nevirapine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:11.000Z"b63cb0f07e929e2ffa1e4bee3eb5178e"4448STANDARDdata/report/2020-10-01/drug_resource/nicotine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:01.000Z"c7d5eb6b7cf49484e40f047ec6630d68"4445STANDARDdata/report/2020-10-01/drug_resource/nilotinib-Drug_Resource_Mappings.xlsx2020-10-01T05:44:55.000Z"15efa344ff40eae2ef4e82da9fdfbd30"4453STANDARDdata/report/2020-10-01/drug_resource/nitrofurantoin-Drug_Resource_Mappings.xlsx2020-10-01T05:45:01.000Z"8a13c48a50d119d81bcb7e37d04196ea"4451STANDARDdata/report/2020-10-01/drug_resource/norfloxacin-Drug_Resource_Mappings.xlsx2020-10-01T05:45:04.000Z"d2f3ea176df600699b5b14faf13c59d2"4456STANDARDdata/report/2020-10-01/drug_resource/nortriptyline-Drug_Resource_Mappings.xlsx2020-10-01T05:45:57.000Z"a8f1b8acea96d741a2faa9a24cc089b4"4448STANDARDdata/report/2020-10-01/drug_resource/olanzapine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:08.000Z"d49d768fac22a5e49248b3002a589720"4448STANDARDdata/report/2020-10-01/drug_resource/oliceridine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:46.000Z"266a8a18e4fb084d9b3cd01fa157d2ff"4450STANDARDdata/report/2020-10-01/drug_resource/omeprazole-Drug_Resource_Mappings.xlsx2020-10-01T05:45:36.000Z"45cb94494ea2467fe645be383d286db2"4447STANDARDdata/report/2020-10-01/drug_resource/ondansetron-Drug_Resource_Mappings.xlsx2020-10-01T05:45:29.000Z"870dbeb4664f4b0d06e3dab6dfa135b9"4447STANDARDdata/report/2020-10-01/drug_resource/oxaliplatin-Drug_Resource_Mappings.xlsx2020-10-01T05:45:12.000Z"75166f2e7d30f86ca41a8c1ac59361b4"4454STANDARDdata/report/2020-10-01/drug_resource/oxazepam-Drug_Resource_Mappings.xlsx2020-10-01T05:45:09.000Z"24c5ddfb9b61e8e55abebf10ebedf58b"4446STANDARDdata/report/2020-10-01/drug_resource/oxcarbazepine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:36.000Z"ea356dfadc24db808bf190a59eade673"4449STANDARDdata/report/2020-10-01/drug_resource/oxycodone-Drug_Resource_Mappings.xlsx2020-10-01T05:44:58.000Z"15f8babec5cf2b5c229636c83fad301c"4443STANDARDdata/report/2020-10-01/drug_resource/paliperidone-Drug_Resource_Mappings.xlsx2020-10-01T05:45:31.000Z"5d8c99907efadfd47cb51ce646a4f102"4453STANDARDdata/report/2020-10-01/drug_resource/palonosetron-Drug_Resource_Mappings.xlsx2020-10-01T05:45:13.000Z"599afebbd7b417a2d51d6d425582c581"4450STANDARDdata/report/2020-10-01/drug_resource/pantoprazole-Drug_Resource_Mappings.xlsx2020-10-01T05:45:30.000Z"11337b7e138616806f73e74124a2c163"4448STANDARDdata/report/2020-10-01/drug_resource/paroxetine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:38.000Z"503424be42a240d77b3ae2d3902e2225"4447STANDARDdata/report/2020-10-01/drug_resource/pazopanib-Drug_Resource_Mappings.xlsx2020-10-01T05:45:00.000Z"cfe22753385f4dec7c2c06f03557cb2e"4449STANDARDdata/report/2020-10-01/drug_resource/peginterferon alfa-2a-Drug_Resource_Mappings.xlsx2020-10-01T05:45:00.000Z"27507452586b9cb8eaa18169586882d6"4462STANDARDdata/report/2020-10-01/drug_resource/peginterferon alfa-2b-Drug_Resource_Mappings.xlsx2020-10-01T05:45:13.000Z"74868d5657d4d4ce523a3790fc8c78fe"4461STANDARDdata/report/2020-10-01/drug_resource/pegloticase-Drug_Resource_Mappings.xlsx2020-10-01T05:44:58.000Z"4fbd0f19b29c2d05b8cba2efff58db4f"4449STANDARDdata/report/2020-10-01/drug_resource/perphenazine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:09.000Z"0b4d6eb514b1bebcde7a766611dab06a"4447STANDARDdata/report/2020-10-01/drug_resource/phenazopyridine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:06.000Z"e8b7bc0b28a487f7d2c81604f745dbfa"4456STANDARDdata/report/2020-10-01/drug_resource/phenprocoumon-Drug_Resource_Mappings.xlsx2020-10-01T05:44:58.000Z"bc6a18c7be2d75fc5b4bea97af8dc80e"4449STANDARDdata/report/2020-10-01/drug_resource/phenytoin-Drug_Resource_Mappings.xlsx2020-10-01T05:45:40.000Z"391341488f4acc9b01f6706f9601fb80"4451STANDARDdata/report/2020-10-01/drug_resource/pimozide-Drug_Resource_Mappings.xlsx2020-10-01T05:44:57.000Z"5524c4f34421234391f9f5346421cc59"4445STANDARDdata/report/2020-10-01/drug_resource/piroxicam-Drug_Resource_Mappings.xlsx2020-10-01T05:45:38.000Z"e81c55c88b92aaf517dcad406910d887"4447STANDARDdata/report/2020-10-01/drug_resource/pitolisant-Drug_Resource_Mappings.xlsx2020-10-01T05:45:26.000Z"a77c23eaeaa9feaa14db5569e2993cad"4450STANDARDdata/report/2020-10-01/drug_resource/platinum-Drug_Resource_Mappings.xlsx2020-10-01T05:45:10.000Z"971613139ac2c3b0cf88df55b170a633"4447STANDARDdata/report/2020-10-01/drug_resource/pravastatin-Drug_Resource_Mappings.xlsx2020-10-01T05:44:58.000Z"651eb260da1e6cb94313d3b4463a76c8"4449STANDARDdata/report/2020-10-01/drug_resource/primaquine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:00.000Z"bdfacfc00a9702b5f1e50823ba239957"4443STANDARDdata/report/2020-10-01/drug_resource/probenecid-Drug_Resource_Mappings.xlsx2020-10-01T05:45:02.000Z"c7c7d2d5e2e7a34daa4016d3a5eb7401"4449STANDARDdata/report/2020-10-01/drug_resource/procainamide-Drug_Resource_Mappings.xlsx2020-10-01T05:45:48.000Z"68849c11889684f7c99179c52da7f4fe"4447STANDARDdata/report/2020-10-01/drug_resource/propafenone-Drug_Resource_Mappings.xlsx2020-10-01T05:45:07.000Z"0ae60b516db9f42c36b275ead8649f46"4448STANDARDdata/report/2020-10-01/drug_resource/propranolol-Drug_Resource_Mappings.xlsx2020-10-01T05:44:56.000Z"03a33687635ad9967e48878f35588d7c"4448STANDARDdata/report/2020-10-01/drug_resource/propylthiouracil-Drug_Resource_Mappings.xlsx2020-10-01T05:45:10.000Z"9b91b553d67e476f2ea4701cd2e5fcbf"4453STANDARDdata/report/2020-10-01/drug_resource/protriptyline-Drug_Resource_Mappings.xlsx2020-10-01T05:44:55.000Z"9b42ca6bd06a108406bb41af5edc529a"4447STANDARDdata/report/2020-10-01/drug_resource/quetiapine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:42.000Z"61f230a55baedd8725688faeedc7997b"4445STANDARDdata/report/2020-10-01/drug_resource/quinidine-Drug_Resource_Mappings.xlsx2020-10-01T05:44:57.000Z"19504b77ec2a868a80b3c39d19b13c15"4446STANDARDdata/report/2020-10-01/drug_resource/quinine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:02.000Z"c3a1e0678c60feb0f7c5566f920cfeca"4445STANDARDdata/report/2020-10-01/drug_resource/rabeprazole-Drug_Resource_Mappings.xlsx2020-10-01T05:45:10.000Z"672c67f9105e53c13b0704d24e464193"4451STANDARDdata/report/2020-10-01/drug_resource/radiotherapy-Drug_Resource_Mappings.xlsx2020-10-01T05:45:06.000Z"16b4f9d59afca9435d285c090673c877"4437STANDARDdata/report/2020-10-01/drug_resource/raloxifene-Drug_Resource_Mappings.xlsx2020-10-01T05:45:48.000Z"c72c466bc0169c440e60e9047ffebcfc"4449STANDARDdata/report/2020-10-01/drug_resource/raltegravir-Drug_Resource_Mappings.xlsx2020-10-01T05:45:51.000Z"f2d5b81ed8fdc5a2cd5c81b370085f73"4447STANDARDdata/report/2020-10-01/drug_resource/rasburicase-Drug_Resource_Mappings.xlsx2020-10-01T05:45:34.000Z"9c547f9e580be0723489f5abddeaff71"4455STANDARDdata/report/2020-10-01/drug_resource/ribavirin-Drug_Resource_Mappings.xlsx2020-10-01T05:45:05.000Z"b87cb654a0cdbb5a654d4243af6b513d"4447STANDARDdata/report/2020-10-01/drug_resource/risedronate-Drug_Resource_Mappings.xlsx2020-10-01T05:45:54.000Z"ba7e2b86c2d6623f6d4aa63917c8b708"4447STANDARDdata/report/2020-10-01/drug_resource/risperidone-Drug_Resource_Mappings.xlsx2020-10-01T05:45:05.000Z"a162bc0b4af04b54c0fd88adaa3b59cc"4449STANDARDdata/report/2020-10-01/drug_resource/rituximab-Drug_Resource_Mappings.xlsx2020-10-01T05:45:03.000Z"369c3a4aca48207939d7b5e2025c2487"4449STANDARDdata/report/2020-10-01/drug_resource/rosiglitazone-Drug_Resource_Mappings.xlsx2020-10-01T05:45:03.000Z"a267e72ee39bc93b38f44eb058c4dd6c"4449STANDARDdata/report/2020-10-01/drug_resource/rosuvastatin-Drug_Resource_Mappings.xlsx2020-10-01T05:45:06.000Z"af8b479f62d0f5a0714d23a1c8bd1aad"4455STANDARDdata/report/2020-10-01/drug_resource/salbutamol-Drug_Resource_Mappings.xlsx2020-10-01T05:45:09.000Z"5095bf1f4652fec8346cba6a7b02d9b5"4453STANDARDdata/report/2020-10-01/drug_resource/salmeterol-Drug_Resource_Mappings.xlsx2020-10-01T05:44:59.000Z"6f170229b355622570ff3b6066ca04f5"4448STANDARDdata/report/2020-10-01/drug_resource/sertraline-Drug_Resource_Mappings.xlsx2020-10-01T05:45:33.000Z"0f5f6475633690544ca30b738f7fb0ef"4446STANDARDdata/report/2020-10-01/drug_resource/sevoflurane-Drug_Resource_Mappings.xlsx2020-10-01T05:45:35.000Z"6bab80101f5e4e28830a718758a65255"4447STANDARDdata/report/2020-10-01/drug_resource/sildenafil-Drug_Resource_Mappings.xlsx2020-10-01T05:45:05.000Z"dc4762baf969cb29bb5fbcfd750cd17b"4448STANDARDdata/report/2020-10-01/drug_resource/simvastatin-Drug_Resource_Mappings.xlsx2020-10-01T05:45:29.000Z"8070d260835aec5e69df0db59422e2b7"4473STANDARDdata/report/2020-10-01/drug_resource/siponimod-Drug_Resource_Mappings.xlsx2020-10-01T05:45:18.000Z"b6451a349c69938feb7d02a31421c2bf"4448STANDARDdata/report/2020-10-01/drug_resource/sirolimus-Drug_Resource_Mappings.xlsx2020-10-01T05:45:16.000Z"be63a721c750dd0a21cf4f0ff96b1211"4448STANDARDdata/report/2020-10-01/drug_resource/sodium nitrite-Drug_Resource_Mappings.xlsx2020-10-01T05:45:18.000Z"1878a91294be86cea10d02e038b03745"4444STANDARDdata/report/2020-10-01/drug_resource/spironolactone-Drug_Resource_Mappings.xlsx2020-10-01T05:45:22.000Z"05d2289958858d88c81e1d8be36ce04d"4451STANDARDdata/report/2020-10-01/drug_resource/streptomycin-Drug_Resource_Mappings.xlsx2020-10-01T05:45:50.000Z"d5821524591512db1bceafaec70c705f"4456STANDARDdata/report/2020-10-01/drug_resource/succinylcholine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:33.000Z"81da146869d265df162e547eaeda92ed"4449STANDARDdata/report/2020-10-01/drug_resource/sulfacetamide-Drug_Resource_Mappings.xlsx2020-10-01T05:45:20.000Z"f88d7990588484abb96a1464f5de7639"4454STANDARDdata/report/2020-10-01/drug_resource/sulfadiazine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:26.000Z"09d721cab657ed6d716cedbe3b5ec36a"4450STANDARDdata/report/2020-10-01/drug_resource/sulfamethoxazole _ trimethoprim-Drug_Resource_Mappings.xlsx2020-10-01T05:45:18.000Z"8e98c4efc7e44a0f1b84786d4170b5d8"4455STANDARDdata/report/2020-10-01/drug_resource/sulfasalazine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:26.000Z"1c5a36a0b19497f356c543eb33a640a7"4452STANDARDdata/report/2020-10-01/drug_resource/sulfisoxazole-Drug_Resource_Mappings.xlsx2020-10-01T05:45:19.000Z"23e88905c058e5558a79d140dd3f9ca0"4461STANDARDdata/report/2020-10-01/drug_resource/sulfonamides-Drug_Resource_Mappings.xlsx2020-10-01T05:45:22.000Z"0abe6e383e4b04a7c4d6a9293ad9e9a3"4446STANDARDdata/report/2020-10-01/drug_resource/sunitinib-Drug_Resource_Mappings.xlsx2020-10-01T05:45:19.000Z"b1d7d53bfc512cf6dd0d16df13eda62e"4454STANDARDdata/report/2020-10-01/drug_resource/tacrolimus-Drug_Resource_Mappings.xlsx2020-10-01T05:45:31.000Z"37c8fb269bb58d179c7e27f5fe7bdc47"4458STANDARDdata/report/2020-10-01/drug_resource/tafenoquine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:14.000Z"98dd20367cba872b7fb46b6025019e3d"4450STANDARDdata/report/2020-10-01/drug_resource/tamoxifen-Drug_Resource_Mappings.xlsx2020-10-01T05:45:31.000Z"b47add484f001c8d37d0ea4888408ba5"4448STANDARDdata/report/2020-10-01/drug_resource/tamsulosin-Drug_Resource_Mappings.xlsx2020-10-01T05:45:22.000Z"7f5f078bb66392be39f2e0d85c10d09b"4446STANDARDdata/report/2020-10-01/drug_resource/tegafur-Drug_Resource_Mappings.xlsx2020-10-01T05:45:32.000Z"4bdb4c8ce337a56057a99ed51136c6bf"4453STANDARDdata/report/2020-10-01/drug_resource/tenofovir-Drug_Resource_Mappings.xlsx2020-10-01T05:45:17.000Z"b69b3a8892f3dca1cdb6117e897007f5"4447STANDARDdata/report/2020-10-01/drug_resource/tenoxicam-Drug_Resource_Mappings.xlsx2020-10-01T05:45:32.000Z"5c3cf8a58a97817894ad34d9b2840c3c"4451STANDARDdata/report/2020-10-01/drug_resource/terbinafine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:17.000Z"294539ab5235089de501df04d4a3e476"4456STANDARDdata/report/2020-10-01/drug_resource/tetrabenazine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:27.000Z"7e1b562d03b2f3bfd9ff6b43462f7e74"4453STANDARDdata/report/2020-10-01/drug_resource/thioguanine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:34.000Z"3e0cb1fb324ad6333c942d6561be68d6"4447STANDARDdata/report/2020-10-01/drug_resource/thioridazine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:23.000Z"c72e3fc56d6b4ef81569fbc04c6ad67f"4448STANDARDdata/report/2020-10-01/drug_resource/timolol-Drug_Resource_Mappings.xlsx2020-10-01T05:45:21.000Z"25a9be29bbdf6679c263a0d3dbd3aa63"4452STANDARDdata/report/2020-10-01/drug_resource/tiotropium-Drug_Resource_Mappings.xlsx2020-10-01T05:45:21.000Z"675f0d4dab75ef017c65b549302cfa35"4450STANDARDdata/report/2020-10-01/drug_resource/tobramycin-Drug_Resource_Mappings.xlsx2020-10-01T05:45:55.000Z"c563c8bbe90c3405538e97518ef233e4"4454STANDARDdata/report/2020-10-01/drug_resource/tolterodine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:23.000Z"4cc401f4a73ce302d9bb431f48fcd5e7"4453STANDARDdata/report/2020-10-01/drug_resource/tramadol-Drug_Resource_Mappings.xlsx2020-10-01T05:45:21.000Z"50bded4c777e65623263daf6346b3665"4448STANDARDdata/report/2020-10-01/drug_resource/triamcinolone-Drug_Resource_Mappings.xlsx2020-10-01T05:45:27.000Z"ef10dc253cba4be65ea92a2b8d4b1af6"4492STANDARDdata/report/2020-10-01/drug_resource/trimipramine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:36.000Z"dc79194e1457b63e78e7c8a36dd800ab"4448STANDARDdata/report/2020-10-01/drug_resource/tropisetron-Drug_Resource_Mappings.xlsx2020-10-01T05:45:33.000Z"31138265b6c74fb338311f623fd5de39"4452STANDARDdata/report/2020-10-01/drug_resource/valbenazine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:50.000Z"d81162f5a1edc15eb1f0caad28f3e557"4452STANDARDdata/report/2020-10-01/drug_resource/valproic acid-Drug_Resource_Mappings.xlsx2020-10-01T05:45:17.000Z"9eb68fda41d9a424377fd69f40ae5e80"4450STANDARDdata/report/2020-10-01/drug_resource/velaglucerase alfa-Drug_Resource_Mappings.xlsx2020-10-01T05:45:16.000Z"52667b88b09673e9427461c1dd4cca3f"4450STANDARDdata/report/2020-10-01/drug_resource/venlafaxine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:25.000Z"ddf7099e1f62c0980a8c5f2ac0e45753"4448STANDARDdata/report/2020-10-01/drug_resource/vitamin c-Drug_Resource_Mappings.xlsx2020-10-01T05:45:15.000Z"01e0b66fe509eed0b682392d8e9787ec"4453STANDARDdata/report/2020-10-01/drug_resource/voriconazole-Drug_Resource_Mappings.xlsx2020-10-01T05:45:28.000Z"7827f49417091862f7b585e2e0e03f6c"4449STANDARDdata/report/2020-10-01/drug_resource/vortioxetine-Drug_Resource_Mappings.xlsx2020-10-01T05:45:15.000Z"d3cef2970abb9cd90eb441bf16da84ad"4449STANDARDdata/report/2020-10-01/drug_resource/warfarin-Drug_Resource_Mappings.xlsx2020-10-01T05:45:25.000Z"9a0ef5bd65535dc2b43a0f322edd3649"4448STANDARDdata/report/2020-10-01/drug_resource/ziprasidone-Drug_Resource_Mappings.xlsx2020-10-01T05:45:46.000Z"7a04e3f694d4ea8b5566eb772fb2e114"4450STANDARDdata/report/2020-10-01/drug_resource/zuclopenthixol-Drug_Resource_Mappings.xlsx2020-10-01T05:45:26.000Z"7e521e5a81d25fd8d6daae10b1dd6838"4452STANDARDdata/report/2020-10-01/frequency/CACNA1S-Frequency.xlsx2020-10-01T05:42:50.000Z"5ff26690d4c8d56defcee659dd62bbd2"7564STANDARDdata/report/2020-10-01/frequency/CYP2B6-Frequency.xlsx2020-10-01T05:42:50.000Z"4826c13092fbe90f45f93e05dda5e19b"20877STANDARDdata/report/2020-10-01/frequency/CYP2C19-Frequency.xlsx2020-10-01T05:42:51.000Z"4092c77b55b65cfdec3055d04239fca3"46964STANDARDdata/report/2020-10-01/frequency/CYP2C9-Frequency.xlsx2020-10-01T05:42:51.000Z"d11422b48ea45f929b1ed44eb404f3f1"45716STANDARDdata/report/2020-10-01/frequency/CYP2D6-Frequency.xlsx2020-10-01T05:42:52.000Z"4f727eb8d504b0641b73159fe2a7fa93"72811STANDARDdata/report/2020-10-01/frequency/CYP3A5-Frequency.xlsx2020-10-01T05:42:52.000Z"aa07d3be2cdbb50e8b7a1fc58a144362"21497STANDARDdata/report/2020-10-01/frequency/CYP4F2-Frequency.xlsx2020-10-01T05:42:52.000Z"1cf54e4c744918cfe14c45281670b3a7"12020STANDARDdata/report/2020-10-01/frequency/DPYD-Frequency.xlsx2020-10-01T05:42:53.000Z"9f50f834e8413ce1fa36ff5036db2c6d"36211STANDARDdata/report/2020-10-01/frequency/HLA-A-Frequency.xlsx2020-10-01T05:42:53.000Z"931345331188508b8a9ed35188b7f7cd"21397STANDARDdata/report/2020-10-01/frequency/HLA-B-Frequency.xlsx2020-10-01T05:42:54.000Z"fac2cae7df2f31975186f586ceacc7a4"24541STANDARDdata/report/2020-10-01/frequency/NUDT15-Frequency.xlsx2020-10-01T05:42:54.000Z"8870372988249d6a851fb7d0c8f9f58a"9814STANDARDdata/report/2020-10-01/frequency/RYR1-Frequency.xlsx2020-10-01T05:42:55.000Z"0cd27953cd87821a005b67c9b469336c"15927STANDARDdata/report/2020-10-01/frequency/SLCO1B1-Frequency.xlsx2020-10-01T05:42:55.000Z"0c4851db8dee9f46191efed62d271959"15152STANDARDdata/report/2020-10-01/frequency/TPMT-Frequency.xlsx2020-10-01T05:42:55.000Z"be9f2cae68cd422197993fc841b0f465"31663STANDARDdata/report/2020-10-01/frequency/UGT1A1-Frequency.xlsx2020-10-01T05:42:56.000Z"041a9743dd0458b7273a3a439f052292"14861STANDARDdata/report/2020-10-01/frequency/VKORC1-Frequency.xlsx2020-10-01T05:42:56.000Z"b63921f06f710df759557eaa9008801b"12663STANDARDdata/report/2020-10-01/gene_cds/CACNA1S-CDS.xlsx2020-10-01T05:43:13.000Z"cf33941f5286782cf80b70fe3e80102a"5555STANDARDdata/report/2020-10-01/gene_cds/CYP2B6-CDS.xlsx2020-10-01T05:43:12.000Z"7678748bb07e154330dc9860696e6b6f"5989STANDARDdata/report/2020-10-01/gene_cds/CYP2C19-CDS.xlsx2020-10-01T05:43:15.000Z"42594fb17f2ca6e4eae982a04889e28b"5797STANDARDdata/report/2020-10-01/gene_cds/CYP2C9-CDS.xlsx2020-10-01T05:43:11.000Z"3029119131cb97bba53f879a320afb8d"5675STANDARDdata/report/2020-10-01/gene_cds/CYP2D6-CDS.xlsx2020-10-01T05:43:16.000Z"795aa3468f481acb43fdd3ba866a98fd"6049STANDARDdata/report/2020-10-01/gene_cds/CYP3A5-CDS.xlsx2020-10-01T05:43:17.000Z"93f9f052ff052b4345429b657494065a"5687STANDARDdata/report/2020-10-01/gene_cds/DPYD-CDS.xlsx2020-10-01T05:43:15.000Z"9faecc2715a4e91a17d810b0a1f05a04"5583STANDARDdata/report/2020-10-01/gene_cds/HLA-A-CDS.xlsx2020-10-01T05:43:14.000Z"aa7ee75fdd81de31c765020207475fb5"5505STANDARDdata/report/2020-10-01/gene_cds/HLA-B-CDS.xlsx2020-10-01T05:43:15.000Z"3435622df6aa6c60af3d866129610097"5737STANDARDdata/report/2020-10-01/gene_cds/NUDT15-CDS.xlsx2020-10-01T05:43:12.000Z"8d12296848070bd72f797bb9418958d8"5679STANDARDdata/report/2020-10-01/gene_cds/RYR1-CDS.xlsx2020-10-01T05:43:16.000Z"04a92e3415a44b78577067bbedef9c72"5554STANDARDdata/report/2020-10-01/gene_cds/SLCO1B1-CDS.xlsx2020-10-01T05:43:14.000Z"f1b180baa08696b1b4bf4ec4db001c80"6056STANDARDdata/report/2020-10-01/gene_cds/TPMT-CDS.xlsx2020-10-01T05:43:12.000Z"57e66367b5cd7087fb1c2bf324219a06"5919STANDARDdata/report/2020-10-01/gene_cds/UGT1A1-CDS.xlsx2020-10-01T05:43:12.000Z"b95abc1cf2536198f55cc18f737de51a"5811STANDARDdata/report/2020-10-01/gene_phenotype/CACNA1S-Phenotypes.xlsx2020-10-01T05:44:07.000Z"aa29f6e743e031cc62b4e6bacce97195"4620STANDARDdata/report/2020-10-01/gene_phenotype/CFTR-Phenotypes.xlsx2020-10-01T05:44:08.000Z"f359b4f78aad1a54a83de825907aa76a"4630STANDARDdata/report/2020-10-01/gene_phenotype/CYP2B6-Phenotypes.xlsx2020-10-01T05:44:08.000Z"71b3c257082ace7655d315cb5ca447a0"5210STANDARDdata/report/2020-10-01/gene_phenotype/CYP2C19-Phenotypes.xlsx2020-10-01T05:44:08.000Z"95c6abaa2c48eea204dd21135849e6c8"5011STANDARDdata/report/2020-10-01/gene_phenotype/CYP2C9-Phenotypes.xlsx2020-10-01T05:44:09.000Z"667eb76e66f58067212c1b37b5dcfa88"5045STANDARDdata/report/2020-10-01/gene_phenotype/CYP2D6-Phenotypes.xlsx2020-10-01T05:44:09.000Z"8cb81b70b8c721a20f3f9578075f8b84"6243STANDARDdata/report/2020-10-01/gene_phenotype/CYP3A5-Phenotypes.xlsx2020-10-01T05:44:09.000Z"6ac1d27addbe305463b26a96df4ea1e9"4678STANDARDdata/report/2020-10-01/gene_phenotype/DPYD-Phenotypes.xlsx2020-10-01T05:44:10.000Z"fb1e5138f1e26deb18a4c20602ae6bd0"4680STANDARDdata/report/2020-10-01/gene_phenotype/G6PD-Phenotypes.xlsx2020-10-01T05:44:10.000Z"dbf0152a0ddf567d2a867cb0faeb67dc"5127STANDARDdata/report/2020-10-01/gene_phenotype/NUDT15-Phenotypes.xlsx2020-10-01T05:44:10.000Z"6e7d43063546777a4c1b31ef59b95504"4672STANDARDdata/report/2020-10-01/gene_phenotype/RYR1-Phenotypes.xlsx2020-10-01T05:44:11.000Z"c69dae9b79c8f08c3f718cf693b7c187"4620STANDARDdata/report/2020-10-01/gene_phenotype/SLCO1B1-Phenotypes.xlsx2020-10-01T05:44:11.000Z"45d5e7f7e5e6dd09423e9376b6a8af13"5003STANDARDdata/report/2020-10-01/gene_phenotype/TPMT-Phenotypes.xlsx2020-10-01T05:44:12.000Z"ff11d9f2c178179bfb188facfc70dbe7"4819STANDARDdata/report/2020-10-01/gene_phenotype/UGT1A1-Phenotypes.xlsx2020-10-01T05:44:12.000Z"8b45cdcd9eafa445bbcd68b6492117ad"4818STANDARDdata/report/2020-10-01/gene_resource/ABCB1-Gene_Resource_Mappings.xlsx2020-10-01T05:43:20.000Z"3966472e0908a578ca6f5b633d02b1b8"4453STANDARDdata/report/2020-10-01/gene_resource/ABCC4-Gene_Resource_Mappings.xlsx2020-10-01T05:43:21.000Z"89ebeddd050967de19a64206cb52ff1c"4453STANDARDdata/report/2020-10-01/gene_resource/ABCG2-Gene_Resource_Mappings.xlsx2020-10-01T05:43:21.000Z"823d30da931d969069248c214156db04"4456STANDARDdata/report/2020-10-01/gene_resource/ABL2-Gene_Resource_Mappings.xlsx2020-10-01T05:43:21.000Z"995abe8b5aef57c2f083243e398c2014"4454STANDARDdata/report/2020-10-01/gene_resource/ACE-Gene_Resource_Mappings.xlsx2020-10-01T05:43:22.000Z"8fd3871743f6112b6e235c48157eed47"4457STANDARDdata/report/2020-10-01/gene_resource/ADD1-Gene_Resource_Mappings.xlsx2020-10-01T05:43:22.000Z"b00f75973c563449927f8ea6d768c3f2"4454STANDARDdata/report/2020-10-01/gene_resource/ADORA2A-Gene_Resource_Mappings.xlsx2020-10-01T05:43:22.000Z"f66eda637eca9535841f440bfefb8ed8"4462STANDARDdata/report/2020-10-01/gene_resource/ADRB1-Gene_Resource_Mappings.xlsx2020-10-01T05:43:23.000Z"be3f72187c23a9a5b2a4aefbbf28e72e"4451STANDARDdata/report/2020-10-01/gene_resource/ADRB2-Gene_Resource_Mappings.xlsx2020-10-01T05:43:23.000Z"64782cca66bf62b93bc065a5fcf59eef"4454STANDARDdata/report/2020-10-01/gene_resource/ANKK1-Gene_Resource_Mappings.xlsx2020-10-01T05:43:24.000Z"26f9ba898ee18a74d31313a3ff566d43"4464STANDARDdata/report/2020-10-01/gene_resource/APOE-Gene_Resource_Mappings.xlsx2020-10-01T05:43:24.000Z"0534bfb3582a9879112e939313ed49e7"4455STANDARDdata/report/2020-10-01/gene_resource/ASL-Gene_Resource_Mappings.xlsx2020-10-01T05:43:24.000Z"736a3911e7063d97446c06833476db3c"4456STANDARDdata/report/2020-10-01/gene_resource/ASS1-Gene_Resource_Mappings.xlsx2020-10-01T05:43:25.000Z"179958518a79c9a5caae6affbde38bfc"4460STANDARDdata/report/2020-10-01/gene_resource/ATIC-Gene_Resource_Mappings.xlsx2020-10-01T05:43:25.000Z"77a3c7584bc76d9b861d02f5e7d03943"4455STANDARDdata/report/2020-10-01/gene_resource/BCHE-Gene_Resource_Mappings.xlsx2020-10-01T05:43:25.000Z"393fa61a111a2ab04e780d6ba777ff7c"4458STANDARDdata/report/2020-10-01/gene_resource/C11orf65-Gene_Resource_Mappings.xlsx2020-10-01T05:43:26.000Z"20778fd714bbe92ec28756c1800d8cb1"4465STANDARDdata/report/2020-10-01/gene_resource/C8orf34-Gene_Resource_Mappings.xlsx2020-10-01T05:43:26.000Z"79921e7af0d9eb8c683b95c515fc484d"4466STANDARDdata/report/2020-10-01/gene_resource/CACNA1S-Gene_Resource_Mappings.xlsx2020-10-01T05:43:27.000Z"9c5bf8f63128cdb3c7c4f246f95cf624"4456STANDARDdata/report/2020-10-01/gene_resource/CALU-Gene_Resource_Mappings.xlsx2020-10-01T05:43:27.000Z"2564f82fcadb3ce1a1ef098e5b52ea37"4459STANDARDdata/report/2020-10-01/gene_resource/CBR3-Gene_Resource_Mappings.xlsx2020-10-01T05:43:27.000Z"afc3f767abd7303e6f7d89e345f86dd7"4457STANDARDdata/report/2020-10-01/gene_resource/CCHCR1-Gene_Resource_Mappings.xlsx2020-10-01T05:43:28.000Z"5abd8df5dfc4f4920daefc2b534f40cf"4464STANDARDdata/report/2020-10-01/gene_resource/CES1-Gene_Resource_Mappings.xlsx2020-10-01T05:43:28.000Z"be9950c6bedbe58c3c1499fe483ded23"4456STANDARDdata/report/2020-10-01/gene_resource/CETP-Gene_Resource_Mappings.xlsx2020-10-01T05:43:29.000Z"657919a529951a29dc565e2a7c5216a5"4456STANDARDdata/report/2020-10-01/gene_resource/CFTR-Gene_Resource_Mappings.xlsx2020-10-01T05:43:29.000Z"0b4a38a3467bab2394be4d1b65b96477"4455STANDARDdata/report/2020-10-01/gene_resource/CHRNA3-Gene_Resource_Mappings.xlsx2020-10-01T05:43:29.000Z"182bff82c63c23e87b7fbb5cc0499258"4458STANDARDdata/report/2020-10-01/gene_resource/COL22A1-Gene_Resource_Mappings.xlsx2020-10-01T05:43:30.000Z"2fce5bfb55a328fca066067a2c69996d"4466STANDARDdata/report/2020-10-01/gene_resource/COMT-Gene_Resource_Mappings.xlsx2020-10-01T05:43:30.000Z"a743b350367a25a227fda64b85165c5b"4453STANDARDdata/report/2020-10-01/gene_resource/COQ2-Gene_Resource_Mappings.xlsx2020-10-01T05:43:30.000Z"cd2b101205473a73b863d2bcbcc9c849"4463STANDARDdata/report/2020-10-01/gene_resource/CPS1-Gene_Resource_Mappings.xlsx2020-10-01T05:43:31.000Z"42843109e2b694ee0314351774a8af5e"4456STANDARDdata/report/2020-10-01/gene_resource/CRHR1-Gene_Resource_Mappings.xlsx2020-10-01T05:43:31.000Z"ee4377c8a7b1d5bfd91e821734b84261"4458STANDARDdata/report/2020-10-01/gene_resource/CRHR2-Gene_Resource_Mappings.xlsx2020-10-01T05:43:32.000Z"58e7cbb44013624d2122dfec91839d68"4459STANDARDdata/report/2020-10-01/gene_resource/CYB5R1-Gene_Resource_Mappings.xlsx2020-10-01T05:43:32.000Z"3e3ec0b9882369eaeba1589397de7c20"4467STANDARDdata/report/2020-10-01/gene_resource/CYB5R2-Gene_Resource_Mappings.xlsx2020-10-01T05:43:32.000Z"fa5617b3fbd320c378b0b0aedc8f70f9"4465STANDARDdata/report/2020-10-01/gene_resource/CYB5R3-Gene_Resource_Mappings.xlsx2020-10-01T05:43:33.000Z"be3b1ecd722d80eb59305cd6ca3f1942"4459STANDARDdata/report/2020-10-01/gene_resource/CYB5R4-Gene_Resource_Mappings.xlsx2020-10-01T05:43:33.000Z"f50b0116188b5943842cc23759aa59ed"4466STANDARDdata/report/2020-10-01/gene_resource/CYP2A7P1-Gene_Resource_Mappings.xlsx2020-10-01T05:43:34.000Z"de5a955153d97f264a612adbc45fcb6a"4462STANDARDdata/report/2020-10-01/gene_resource/CYP2B6-Gene_Resource_Mappings.xlsx2020-10-01T05:43:34.000Z"af393606d049c3a5d01374294cae7a14"4459STANDARDdata/report/2020-10-01/gene_resource/CYP2C19-Gene_Resource_Mappings.xlsx2020-10-01T05:43:34.000Z"41fc5b62b907b5ce77ab4454de230263"4458STANDARDdata/report/2020-10-01/gene_resource/CYP2C8-Gene_Resource_Mappings.xlsx2020-10-01T05:43:35.000Z"bfebf4e9e3b214f3325632c03436a7a7"4457STANDARDdata/report/2020-10-01/gene_resource/CYP2C9-Gene_Resource_Mappings.xlsx2020-10-01T05:43:35.000Z"7f39229dc958e43876826d070a356718"4458STANDARDdata/report/2020-10-01/gene_resource/CYP2D6-Gene_Resource_Mappings.xlsx2020-10-01T05:43:35.000Z"0af3614987ba6190542d64aaf8e5ce2d"4458STANDARDdata/report/2020-10-01/gene_resource/CYP3A4-Gene_Resource_Mappings.xlsx2020-10-01T05:43:36.000Z"8d080e68a9bb83d4c3dd238c7c7f519e"4460STANDARDdata/report/2020-10-01/gene_resource/CYP3A5-Gene_Resource_Mappings.xlsx2020-10-01T05:43:36.000Z"0476f94827ca92d47b372fd039190499"4458STANDARDdata/report/2020-10-01/gene_resource/CYP4F2-Gene_Resource_Mappings.xlsx2020-10-01T05:43:37.000Z"19dc7ea875ceee8366f590df46f4b568"4460STANDARDdata/report/2020-10-01/gene_resource/DPYD-Gene_Resource_Mappings.xlsx2020-10-01T05:43:37.000Z"82f4e07a5fdbf042d306f1c0d7e67c84"4458STANDARDdata/report/2020-10-01/gene_resource/DRD2-Gene_Resource_Mappings.xlsx2020-10-01T05:43:37.000Z"128fb85ddec41858bfd15482845bcb81"4459STANDARDdata/report/2020-10-01/gene_resource/DYNC2H1-Gene_Resource_Mappings.xlsx2020-10-01T05:43:38.000Z"8656fa772b745ae2f69d1784c6dc5bb2"4463STANDARDdata/report/2020-10-01/gene_resource/EGF-Gene_Resource_Mappings.xlsx2020-10-01T05:43:38.000Z"a399ad32e5902eeb8b9f5247f63ae549"4458STANDARDdata/report/2020-10-01/gene_resource/EPHX1-Gene_Resource_Mappings.xlsx2020-10-01T05:43:39.000Z"09592801965a798862e91ad479c38e00"4459STANDARDdata/report/2020-10-01/gene_resource/ERCC1-Gene_Resource_Mappings.xlsx2020-10-01T05:43:39.000Z"db1bc273b1b5e5d3040b0624c4c65ddd"4456STANDARDdata/report/2020-10-01/gene_resource/F5-Gene_Resource_Mappings.xlsx2020-10-01T05:43:40.000Z"32917384035ecc032a20dc1043dc35af"4457STANDARDdata/report/2020-10-01/gene_resource/FCGR3A-Gene_Resource_Mappings.xlsx2020-10-01T05:43:40.000Z"ee35b94f2eed830cd3d96f839968f5d5"4459STANDARDdata/report/2020-10-01/gene_resource/FDPS-Gene_Resource_Mappings.xlsx2020-10-01T05:43:40.000Z"1fedd83e42c7a0caa14f73b043d66712"4458STANDARDdata/report/2020-10-01/gene_resource/FKBP5-Gene_Resource_Mappings.xlsx2020-10-01T05:43:41.000Z"583518d02a8324f3f178edb1fa8c8081"4459STANDARDdata/report/2020-10-01/gene_resource/FLOT1-Gene_Resource_Mappings.xlsx2020-10-01T05:43:41.000Z"d533da34960825ea6e1006f08eedd436"4459STANDARDdata/report/2020-10-01/gene_resource/G6PD-Gene_Resource_Mappings.xlsx2020-10-01T05:43:41.000Z"dd1f87aa27cbbb2a1e8c9cc4efc03589"4458STANDARDdata/report/2020-10-01/gene_resource/GBA-Gene_Resource_Mappings.xlsx2020-10-01T05:43:42.000Z"1744a19b53f84e47266159a9379306ec"4458STANDARDdata/report/2020-10-01/gene_resource/GGCX-Gene_Resource_Mappings.xlsx2020-10-01T05:43:42.000Z"b96f91e14d1f0cf2fa64ac63af78de58"4457STANDARDdata/report/2020-10-01/gene_resource/GNB3-Gene_Resource_Mappings.xlsx2020-10-01T05:43:42.000Z"84a83215bcf9d67580f09f3621d60e7a"4455STANDARDdata/report/2020-10-01/gene_resource/GP1BA-Gene_Resource_Mappings.xlsx2020-10-01T05:43:42.000Z"e87606c9ddcb592bbbcb6f301c3d4023"4459STANDARDdata/report/2020-10-01/gene_resource/GRIK4-Gene_Resource_Mappings.xlsx2020-10-01T05:43:43.000Z"112d1f6539284e012989c5cc6f2eaed8"4461STANDARDdata/report/2020-10-01/gene_resource/GRK5-Gene_Resource_Mappings.xlsx2020-10-01T05:43:43.000Z"e883581e14dd6e98a140079bae60daf2"4452STANDARDdata/report/2020-10-01/gene_resource/GSTM1-Gene_Resource_Mappings.xlsx2020-10-01T05:43:43.000Z"d9fdadc8658b59ba0437904489c6b615"4456STANDARDdata/report/2020-10-01/gene_resource/GSTP1-Gene_Resource_Mappings.xlsx2020-10-01T05:43:44.000Z"61bf81c5e29c892d09f45b4138dca686"4458STANDARDdata/report/2020-10-01/gene_resource/HAS3-Gene_Resource_Mappings.xlsx2020-10-01T05:43:44.000Z"763b4dd3dfea0b3cdd80fc5ea85c401a"4457STANDARDdata/report/2020-10-01/gene_resource/HLA-A-Gene_Resource_Mappings.xlsx2020-10-01T05:43:44.000Z"ee9029254878949d94b8c1ec73dd75b0"4458STANDARDdata/report/2020-10-01/gene_resource/HLA-B-Gene_Resource_Mappings.xlsx2020-10-01T05:43:45.000Z"fdf058ebf69d5e07eb217ce9a6d274dd"4459STANDARDdata/report/2020-10-01/gene_resource/HLA-C-Gene_Resource_Mappings.xlsx2020-10-01T05:43:45.000Z"de848586f17f4a887b11dd6651dd042a"4457STANDARDdata/report/2020-10-01/gene_resource/HLA-DPB1-Gene_Resource_Mappings.xlsx2020-10-01T05:43:45.000Z"c2eee8f7e2ee757f01195e6ccb673acb"4462STANDARDdata/report/2020-10-01/gene_resource/HLA-DQA1-Gene_Resource_Mappings.xlsx2020-10-01T05:43:46.000Z"87c29eda60bcef9bf0f6807a821b55cc"4463STANDARDdata/report/2020-10-01/gene_resource/HLA-DRB1-Gene_Resource_Mappings.xlsx2020-10-01T05:43:46.000Z"2b4ec9e1823eb00efcf1da9a43650bc5"4464STANDARDdata/report/2020-10-01/gene_resource/HMGCR-Gene_Resource_Mappings.xlsx2020-10-01T05:43:46.000Z"855164bb072b7dedc7a3139cc133d560"4453STANDARDdata/report/2020-10-01/gene_resource/HPRT1-Gene_Resource_Mappings.xlsx2020-10-01T05:43:47.000Z"643ca32c2eccd06870d8e9ee825b434e"4460STANDARDdata/report/2020-10-01/gene_resource/HTR1A-Gene_Resource_Mappings.xlsx2020-10-01T05:43:47.000Z"d0e16ecf886eee632a8d5bffd46a0b19"4458STANDARDdata/report/2020-10-01/gene_resource/HTR2A-Gene_Resource_Mappings.xlsx2020-10-01T05:43:47.000Z"f08563d1aa2bdff822ab649c72866f06"4457STANDARDdata/report/2020-10-01/gene_resource/HTR2C-Gene_Resource_Mappings.xlsx2020-10-01T05:43:48.000Z"4a8cbd6e3d47f38f0d01281d182eb395"4455STANDARDdata/report/2020-10-01/gene_resource/IFNL3-Gene_Resource_Mappings.xlsx2020-10-01T05:43:48.000Z"018c31f9e8d01d1931e07b18159c07e3"4465STANDARD